GUTS
Fractyl HealthFDocument history
Transcripts and related coverage stored for GUTS. Related articles may discuss other companies and are not verified issuer releases.
Related articleQuarter not tagged2026-11-13Fractyl Health (GUTS) Q3 2026 Earnings Call Transcript
Motley Fool
Fractyl Health (GUTS) Q3 2026 Earnings Call Transcript
Image source: The Motley Fool. Thursday, Nov. 12, 2026 - Head of Investor Relations and Corporate Development - Brian Luque - Chief Executive Officer - Harith Rajagopalan - Chief Financial Officer - Lara Smith Weber Operator: Good afternoon, and welcome to the Fractyl Health Third Quarter 2026 Financial Results and Business Update Call. As a reminder, this conference call is being recorded. [Operator Instructions] I will now turn the call over to Brian Luque, Head of Investor Relations and Corporate Development at Fractyl. Brian, you may now begin. Brian Luque: Thank you. This afternoon, we issued a press release that outlines the topics we plan to discuss today. This release is available at www.fractyl.com under the Investors tab. Joining us on the call today are Dr. Harith Rajagopalan, Chief Executive Officer; and Lara Smith Weber, Chief Financial Officer. Before we begin, one change to our format. For the first time, we invited all of our shareholders to submit and vote on questions for management through Say by Robinhood. After our prepared remarks, I will read a selection of the most voted shareholder questions, and then the operator will open the line to our covering analysts. Thank you to everyone who took part. During this call, we make forward-looking statements, which involve risks and uncertainties that may cause actual results to differ materially from our forward-looking statements. We provide a comprehensive list of risk factors in our SEC filings, including the quarterly report on Form 10-Q filed today, which I encourage you to review. Any forward-looking statements on the call are subject to substantial risks and uncertainties and speak only as of the call's original date, and we undertake no obligation to update or revise any of these statements even if subsequent events cause the company's views to change. It is now my pleasure to pass the call over to Harith. Harith Rajagopalan: Thank you, Brian. Good afternoon, everyone. Nearly 30 million Americans are now on GLP-1 therapy. Approximately 1 million are discontinuing GLP-1s each month. Yet, those who take GLP-1s, only 1 in 12 Americans remain on them for obesity at the end of 3 years. What happens for the 11 out of 12 who stop? On average, 85% of patients regain weight and roughly 2/3 of the weight comes back within a year. That is a systemic pattern driven by biology, not an individual fai…Read full documentShow less
Image source: The Motley Fool. Thursday, Nov. 12, 2026 - Head of Investor Relations and Corporate Development - Brian Luque - Chief Executive Officer - Harith Rajagopalan - Chief Financial Officer - Lara Smith Weber Operator: Good afternoon, and welcome to the Fractyl Health Third Quarter 2026 Financial Results and Business Update Call. As a reminder, this conference call is being recorded. [Operator Instructions] I will now turn the call over to Brian Luque, Head of Investor Relations and Corporate Development at Fractyl. Brian, you may now begin. Brian Luque: Thank you. This afternoon, we issued a press release that outlines the topics we plan to discuss today. This release is available at www.fractyl.com under the Investors tab. Joining us on the call today are Dr. Harith Rajagopalan, Chief Executive Officer; and Lara Smith Weber, Chief Financial Officer. Before we begin, one change to our format. For the first time, we invited all of our shareholders to submit and vote on questions for management through Say by Robinhood. After our prepared remarks, I will read a selection of the most voted shareholder questions, and then the operator will open the line to our covering analysts. Thank you to everyone who took part. During this call, we make forward-looking statements, which involve risks and uncertainties that may cause actual results to differ materially from our forward-looking statements. We provide a comprehensive list of risk factors in our SEC filings, including the quarterly report on Form 10-Q filed today, which I encourage you to review. Any forward-looking statements on the call are subject to substantial risks and uncertainties and speak only as of the call's original date, and we undertake no obligation to update or revise any of these statements even if subsequent events cause the company's views to change. It is now my pleasure to pass the call over to Harith. Harith Rajagopalan: Thank you, Brian. Good afternoon, everyone. Nearly 30 million Americans are now on GLP-1 therapy. Approximately 1 million are discontinuing GLP-1s each month. Yet, those who take GLP-1s, only 1 in 12 Americans remain on them for obesity at the end of 3 years. What happens for the 11 out of 12 who stop? On average, 85% of patients regain weight and roughly 2/3 of the weight comes back within a year. That is a systemic pattern driven by biology, not an individual failure of willpower, and it doesn't have to be this way. So why does the weight come back? We believe the answer is in the gut. Modern unhealthy diets accelerate cellular aging in the gut. In plain terms, those changes make us more prone to obesity. And the aging gut may retain a metabolic memory that perpetuates disease. GLP-1 medicines have proven that dramatic weight loss is possible, but they neither reverse the underlying cellular agent causing obesity nor regenerate a healthy gut. They leave the underlying problem untouched. Revita aims to do both. It is designed to reset the gut's metabolic memory as a onetime outpatient procedure designed to ablate the damaged unhealthy lining of the duodenum to allow healthier tissue to regenerate in its place. LASIK for obesity. It means the gut is now working with, not against, a patient's weight loss program. This means the potential for better overall health and weight loss that can actually last even after the drugs are stopped. Last month, we put that idea through the most rigorous stress test we could conceive. REMAIN-1, in which patients were driven to achieve rapid and profound weight loss and then stopped high-dose tirzepatide outright. It's the most extreme example of what could happen in the real world and the study met its 6-month co-primary endpoint with high statistical significance. Today, I want to take you through 3 things. Number one, what the REMAIN-1 top line showed why we believe it is clinically meaningful? And what to expect next as we look to complete the study in Q1 2027. Number two, why the market is ready for Revita and number three, how we have rebuilt fractal around it. Then Laura will take you through the quarter. I will close on 3 milestones in front of us, submitting our de novo marketing application later this quarter 12-month co-primary and key secondary end points in the first quarter of 2027 and clarity on the CMS rapid reimbursement rule. All value-accretive milestones funded with the cash we have on hand. Let me take each in turn. What did REMAIN-1 top line show? We designed REMAIN-1 to provide a rapid and clean assessment of Revita's safety and efficacy in the post GLP-1 weight maintenance setting. Adults with obesity who had never taken a GLP-1 started tirzepatide, stayed on it until they had lost at least 15% of their body weight. On average, they lost 18.3% over about 25 weeks and about half reached the maximum 15-milligram dose. Then the drug was stopped and participants were randomized 2:1 to Revita or to a sham procedure double-blind, 308 participants make up the modified intention to treat population. The study met its 6-month co-primary endpoint with high statistical significance, p-value of 0.0023. Revita participants kept about 80% of the weight they lost on the tirzepatide and whichever way we look across primary and every prespecified sensitivity analysis, the result was highly statistically significant with 2 to 3 0s in the p-value. If anything, we believe the comparison with sham is conservative in participation was about 3 times as likely as Revita participants to restart an anti-obesity medication, which potentially masks the true effect of Revita. Two findings I want you to remember. First, the effect grew over time. The gap between Revita and sham widened at every visit from month 1 to 3 to 6 and nearly doubled between months 3 and 6. In our pilot, Revita patients leveled off at about 80% of their weight loss retained at 1 year. And so far, the pivotal is tracking that experience. Second, what this means for an individual patient, 1 in 3 Revita participants were weight stable or had lost more weight 6 months after stopping tirzepatide, nearly half kept at least 80% of their weight loss. And when we apply the method for our 12-month responder endpoint at 6 months as a post hoc analysis, more than 97% of Revita participants maintained clinically meaningful weight loss at 1 year against a performance goal of greater than 50%. The formal test of that second co-primary endpoint will come with our 12-month data in the first quarter of 2027. We also continue to see a dose response with ablation length. In our pilot, the benefit was clearest above 14 centimeters. With a much larger study, we now have the numbers and granularity to see it more precisely. In a post hoc analysis, separation from sham begins at a dose as low as 12 centimeters and progressively better with a longer ablation for the full length of the duodenal or roughly 20 centimeters. Our best-performing patients received a full treatment of 20 centimeters or more, and they achieved less than half the regain of sham. REMAIN-1 contributes not only the evidence to support our planned de novo submission later this quarter, but also the evidence to inform how to train physicians to perform the procedure after approval for maximum effect. Each additional 2 centimeters takes about 2 centimeters and physicians lengthen their ablations as they gained experience in the study. With the 6-month and 12-month data, we will have adequate information to define the appropriate treatment length for real-world implementation. And there's an added benefit to the dose response we are observing. Given the novelty of the duodenum as a target, dose response builds credibility and target validation, something we are hearing from physicians over and over again. On safety, the profile was what we have come to expect from Revita. There were no device or procedure-related serious adverse events, no deaths, no unanticipated adverse device effects. Related events were mostly mild and the vast majority of them occurred only on the day of the procedure. So the next clinical milestone for REMAIN-1 is clear. In the first quarter of 2027, we expect top line 12-month data from the second co-primary endpoint. If both co-primary endpoints are met our key secondary endpoints, including complete ablation and higher run-in weight loss will then be formally tested in sequence. Here is what success looks like at 12 months. First, we meet the second co-primary endpoint, which is the prespecified performance goal. Based on what we see at 6 months, we're highly confident in that result. Second, at longer ablation lengths, we want to see even greater effect as we showed at 6 months. We hope to see the Revita arm with a complete treatment maintain a majority of its weight loss at 1 year. The physicians we've been talking to and our patient market research tells us that a full ablation should be the expected standard procedure for Revita if it is authorized. Now let's step out of the data and into the doctor's office. In a consumer market, physicians will not talk to patients about placebo-adjusted differences, they will say, here's what you can expect to keep. REMAIN-1 top line clearly demonstrated that patients have the potential to retain the majority of their hard-won weight loss with a low risk of serious side effects. Now let's turn to why the market is ready for Revita. At our Commercial Strategy Day in September, we laid out why we see Revita's launch as market activation, not market creation. Our commercial model is a targeted and efficient launch at bariatric and metabolic centers of excellence. -- the patients, the interventional physicians and surgeons, the procedure rooms and the payer precedent already exists. What is missing is durable off-ramp. Each year, roughly 4 million Americans stop a GLP-1 after losing at least 15% of their body weight and fall within the BMI range we studied. That is a population that REMAIN-1 enrolled. Those patients are concentrated in ASMBS centers of excellence that we can name. There are about 1,000 accredited bariatric centers in the United States. Our launch plan focuses on the top 100 to 200 of them, many of them sites that we already know from our clinical program. Each of those centers already sees more than 2,000 GLP-1 patients a year, and we modeled 250 to 500 Revita procedures per center per year at maturity well within each center's capacity. And the metabolic interventionalist physicians in those centers already have the skills and the enthusiasm for procedures like Revita. And REMAIN-1 half day of training and about 4 proctored cases brought them to proficiency. That backed by a capital-efficient center of excellence model is why we believe a commercial team of tens of people, not hundreds can support a launch. In 2025, before our pivotal data, we commissioned third-party market research across roughly 750 patients, prescribers, and hospital stakeholders, Three findings stand out from that market research: First, patients understand the risks of discontinuation very well. Nearly 8 in 10 patients were both already aware of and very concerned about regaining weight after stopping a GLP-1. Over 80% ranked a onetime procedure that lets them stop their GLP-1 without regaining weight as among the features that matter most to them. The patients most interested were those who are currently on a GLP-1. Amazingly, despite the very well-known benefits of long-term GLP-1 treatment, 1 in 3 survey GLP-1 users would prefer to stop taking their GLP-1 and undergo a hypothetical endoscopic procedure than continue staying on their drug. And prescribers told us evidence that moves them most is what happens to the patients in the Revita arm, which is exactly how REMAIN-1 reads out. Second, patients want to make this decision with their doctor. And that is good news for Revita. The metabolic interventionalists, we are building our launch around already have these patients in their practices and are excited about offering them Revita if it is cleared. Third, the physicians who perform procedures are ready. Interventional practices in the research, we're highly interested in adopting Revita and their concerns centered on economics and validating outcomes, which is exactly what our reimbursement work and REMAIN-1 are designed to address. That is why our launch centers on metabolic interventionalists the bariatric surgeons and advanced endoscopists, who already manage GLP-1 patients and already performed procedures. The independent physicians who joined our Commercial Strategy Day and our data calls over the past several months, told us this conversation as part of their practice day in and day out. One question that we often hear, do oral GLP-1s change this picture. We don't think so. What patients valued most was the ability to stop either a weekly injection or a daily pill. A daily pill may change how a patient takes a GLP-1, it may increase the number who started GLP-1, but it does not change their perspective on whether they want to stay on a GLP-1. Our view is simple, every initiation, oral or injectable is a potential future discontinuation risk for which an off-ramp is a needed treatment alternative. This brings me to reimbursement where there are 3 components and all 3 have made significant headway in the past quarter. On coding, the AMA published Category III CPT Code 1122T on October 2 and a dedicated code for Revita procedure that will be effective January 1, 2027. On payment, if Revita qualifies for CMS transitional pass-through payment, which we believe it will, that could help hospitals recover the catheter cost and their contribution margin during the early launch period. And on coverage, CMS has proposed RAPID, a new coverage pathway that could align Medicare coverage with FDA authorization for breakthrough devices. The open question for Revita is how devices like ours with pivotal trials already underway, get to participate in Rapid. The response during the common period was overwhelming. More than 160 comments were filed, nearly all of them supported an on-ramp, including the major medical societies and the device industry associations, MDMA and AdvaMed. Several went further and named Revita specifically ASGE and ASMBS pointed to Revita as an example of the devices for which CMS needs to find a solution. They were joined by a joint AGA and ASGE letter, the Obesity Action Coalition Patient Advocacy Group and leading bariatric and endoscopic physicians writing on their own behalf. We expect to learn whether CMS adopts an on-ramp by early January. If Revita is included, it could offer a materially better coverage position than our base case assumes. And remember, the Medicare GLP-1 bridge program is expanding GLP-1 access for seniors through the end of 2027. And a federal program is creating and time limiting the exact population that Revita is designed to serve. The patients are there. The physicians are there, the payment pathway is taking shape. Revita is being built to be the missing piece. Now let's talk about how we have rebuilt Fractyl around Revita. On October 21, in consultation with our Board, we decided to streamline the company's operations, workforce and business to become hyper focused on Revita's near-term objectives. The goal is to get through our upcoming clinical, regulatory and early commercialization milestones as efficiently as possible. That meant reducing our workforce by approximately 45% and discontinuing internal development of our Rejuva gene therapy program. Given the current financing environment for biotech, it is our duty to adapt to the reality of the situation and we have. This was a painful thing to go through. These decisions affect colleagues who helped bring Revita to this point. I value each one, and I'm grateful for everything they have done to bring Fractyl to where it is today. And as these changes take effect and our pivotal study spending winds down, we expect our quarterly operating cash spending to fall by approximately half to approximately $8 million by the end of the second quarter of 2027. Our cash runway now extends into the second quarter of 2027 through our planned de novo submission and our 12-month pivotal data. We also added to our Board this month welcoming Mike Wartell as an independent director. Michael brings extensive experience serving on public and private company boards and we're glad to have his perspective as we execute on the milestones ahead. I also want to thank Jay Caplan, our wonderful co-founder and former President, my dear friend, who has been instrumental in helping build this company. Jay retired from his executive roles at the end of October. The result of all of this is a smaller, more efficient, more focused company with 1 priority: Delivering on Revita's near-term milestones. Lara? Lara Weber: Thank you, Harith. The story of this quarter is discipline. Lower operating expenses today and a clear path to cutting our quarterly operating cash spending roughly in half. Research and development expenses were $12.5 million for the third quarter of 2026 and compared with $17.5 million for the same period in 2025. The decrease of $5 million was primarily related to reduced spending on our Revita and Rejuva programs as well as lower personnel-related expenses. SG&A expenses were $6.2 million for the quarter compared with $5.2 million for the same period in 2025. The increase of $1 million was primarily driven by higher personnel-related and stock compensation expenses. We reported a net loss of $14.2 million for the third quarter of 2026 compared with a net loss of $45.6 million for the same period in 2025. The $31.5 million decrease was driven by a $25.7 million favorable change in the noncash fair value of our warrant liabilities and a $4 million reduction in operating expenses with smaller movements in the fair value of notes payable and interest income. Adjusted EBITDA was negative $16 million for the quarter compared with negative $20.8 million in the third quarter 2025, a $4.8 million improvement driven by reduced operating expenses, excluding stock compensation. As of September 30, 2026, we had $31.5 million in cash and cash equivalents. I want to draw your attention to 1 point on our run rate. Cash used in operations was just below $16 million in the third quarter, which still reflects REMAIN-1 pivotal cohort spending and our cost structure before the reprioritization. As cost reductions take effect and pivotal expenditures decline, we expect quarterly operating cash spending to be reduced by approximately 50% and to approximately $8 million by the end of the second quarter of 2027. We expect to incur approximately $2 million in severance and related charges, the majority in the fourth quarter. Based on our current operating plan and anticipated expense reductions, we believe our cash position will be sufficient to fund operations into the second quarter of 2027 through our planned de novo submission and the anticipated top line 1-year data from the REMAIN-1 pivotal cohort. With that, I'll turn it back to Harith. Harith Rajagopalan: Thank you, Lara. And let me close where I started. Revita is designed to reset the gut's metabolic memory, REMAIN-1 met its 6-month co-primary endpoint with high statistical significance in the most rigorous stress test that we could conceive. The patients and physicians are there and the payment pathway is taking shape. We have rebuilt Fractyl around Revita with the runway to get through the milestones directly in front of us. Over the next several months, there are 3 milestones I want you to be focused on: First is the submission of our de novo marketing application, which we plan to begin in the late fourth quarter of 2026; and second, our 12-month pivotal data in the first quarter of 2027, including the second co-primary endpoint, key secondary endpoints and dose-response analyses. Success there means meeting the regulatory performance goal and roughly half the regain of sham at full ablation lengths; third, clarity on the CMS rapid reimbursement rule. We expect to learn by Q1, whether CMS adopts an on-ramp for devices like Revita that have pivotal trials already underway, and we are optimistic that they will find such a path. Beyond those, we see a potential FDA marketing authorization in late 2027 and a potential U.S. commercial launch in early 2028. I want to thank the patients and remain on who have trusted us with their health and their persistence, the investigators and operators who have executed this trial with real skill, our employees, including the colleagues leaving us this quarter, whose focused through an unusually demanding stretch has been exceptional, and I want to thank our shareholders, including the many individual investors who sent us questions for the very first time, whose conviction in the science makes all of it possible. This is a moment Fractyl was built for. We've never been more focused on delivering on what comes next. Brian, let's start with those questions. Brian Luque: Thanks, Harith. We'll begin with questions submitted by our shareholders through Say by Robinhood. I'll read a selection of the most voted questions, combining a few of that overlap. So the first question is, what concrete steps are the Board and management taking to restore credibility with investors, including institutional investors? Harith Rajagopalan: Thank you for asking directly. Credibility is earned by doing what we say we will do, and I would point to 4 steps: First, the data, REMAIN-1 met its 6-month co-primary endpoint in a randomized double-blinded sham-controlled study with high statistical significance; second, discipline. With our Board, we made difficult decisions last month to focus the company entirely on Revita and to put us on a path to cut quarterly operating cash spending by approximately half; third, governance. This month, we added Mike Wartell to our Board as an independent director; and fourth, we remain committed to keeping a continuous dialogue with our institutional and retail investors alike. From here, we expect to be judged on execution, de novo submission, 12-month data and clarity on Rapid. Brian Luque: Great. The next question combines a few on funding. How does the company plan to fund its upcoming milestones? And are you exploring strategic partners, licensing agreements or a potential acquisition? Lara Weber: We ended the quarter with $31.5 million in cash and cash equivalents. Based on our current operating plan, we believe that, that is sufficient to fund operations into the second quarter of 2027 through our planned de novo submission and the 12-month REMAIN-1 data. The reprioritization we announced in October is expected to reduce quarterly operating cash spending by approximately 50% to approximately $8 million by the end of the second quarter of 2027. So based on our current operating plans, the milestones who we described are funded with the cash we have on hand. Beyond those milestones, we will need additional capital to bring Revita to market, and we will weigh every option with shareholder value in mind. On the strategic side, we do not comment on specific discussions, and we would update you only if there was something definitive to report. What I can say is that every milestone we deliver potentially expands our options. Brian Luque: Great. And the last shareholder question is about ablation length. Your data showed better results with longer ablations. What training or procedural steps are you taking so that patients in the real-world practice consistently receive a full length of treatment or 20-plus centimeters? Harith Rajagopalan: This is a great question. The answer is quite simple, actually. In our analysis, we saw a better treatment effect at longer ablation lengths like what we have seen in prior studies and patients who reached 20 centimeters in the post-hoc analysis saw the greatest effect with no associated safety signal observed. Physicians in REMAIN-1 reached that length with the current device. Each additional 2 centimeters takes about 2 minutes, and these findings inform the procedural parameters that we've proposed to the FDA. And if Revita is approved, will also inform our physician training program for launch. Brian Luque: Great. That concludes the shareholder questions. Thank you to everyone who submitted. Operator, please open the line for analysts. Operator: [Operator Instructions] Thank you. At this time, we will conduct a question-and-answer session. And our first question will come from the line of Angela Qian of Canaccord Genuity. Angela Qian: This is Angela on for Whitney. A question on the Medicare patient population, it sounds like that population could really represent a significant portion of Revita patients given the bridge program ending at the end of '27. And then since you're targeting the top 10% to 20% of high-volume accredited metabolic and bariatric centers, can you maybe share what proportion of patients at those centers are currently Medicare patients? Harith Rajagopalan: Sure. Thank you, Angela, for the question. I would say that, yes, we are planning an early launch predicated on Medicare patients. The question that you're asking is complicated because until about 6 months ago, relatively few patients were Medicare patients. But in our conversations in the last several weeks alone, what we are observing is that every one of our centers with whom we're in dialogue are seeing a rapid increase in the number of Medicare patients who are specifically seeking GLP-1s through this bridge program. We heard earlier in the quarter that from David Ricks, the CEO of Eli Lilly, that 700,000 patients had joined the GLP-1 bridge program across the United States. That number is a fraction of what Medicare anticipates will be in the United States. It will be roughly 4 million to 5 million people on the GLP-1 bridge by around this time next year. So if you assume that there's roughly 30 million people on GLP-1s today, and let's say that's a relatively steady-state number. It's going to grow by about 4 million to 5 million of GLP-1 patients who are from the Bridge program alone. That's our expectation. Angela Qian: Got it. If I could just follow-up quickly with another question that piggybacks off of one of the shareholder questions. Since you had seen greater lengths of ablation results and greater efficacy, I guess, do you expect physicians to potentially require longer training than what was previously estimated since you might have to ablate a longer length? Harith Rajagopalan: Well, before beginning REMAIN-1, we believe that the length of duodenal ablation could be an important determinant of treatment effect. And as you saw from our midpoint study and our 6-month data, we've observed an encouraging relationship between ablation length and efficacy. In our exploratory analysis, patients receiving longer ablation lengths did experience greater reduction in weight regain. And the practical implication is that if longer treatment lengths are truly associated with greater benefit, and we'll see that 12-month data soon, we believe that physicians can and will be trained to deliver those treatments consistently. Remember, each additional 2 centimeters of ablation adds approximately 2 minutes to the procedure. We're not talking about an entirely different intervention or a fundamentally different skill set, we're talking about optimizing the extent of treatment within a standardized endoscopic procedure with our existing tools and skills. We've seen physicians improve their ability to deliver longer treatments as they gain experience. And when you're treating more tissue or delivering a higher dose, the therapeutic window and safety matters, so I just want to reiterate, Importantly, we have not observed a safety signal suggesting that longer ablation lengths are associated with any additional risk of serious adverse events and the data that we've evaluated to date. Operator: Our next question will come from the line of Mike DiFiore of Evercore. Michael DiFiore: Two for me. One is regarding the potential Class II classification of Revita. Obviously, the final pathway decision follows a review of complete safety data set. But regarding the 2 events in 1 Revita patient, that were deemed possibly related to the device or procedure, which included GI hemorrhage and acute blood loss anemia, how do you expect the FDA to treat these possibly related events when it determines the class? Harith Rajagopalan: So I can't speak for the FDA, but I can speak to this adverse event that you're mentioning. So just for those who may be new to the story, 1 patient who experienced possibly device or procedure-related serious adverse events as deemed by an independent DSMB during the course of the study. This is an individual who was on 2 different nonsteroidal anti-inflammatory drugs at the same time, which is contraindicated for a different indication, totally unrelated to Revita or the disease that we are targeting here. And we know that NSAIDs carry a risk of GI bleed. This patient also had 2 endoscopies performed during the active bleeding episode and no bleeding was -- source was identified in the duodenum despite an active effort to try to find one and no intervention was ultimately performed. It's only because the person was in the study that we believe that this was classified as possibly. We believe that the study team did everything they could to determine whether there was a cause from the ablation and none was found. So we do not think this is going to change anyone's perception of Revita's safety profile. Michael DiFiore: Very helpful. Just 1 quick follow-up. What indication statement are you proposing? Is it tied to prior weight loss of at least 15% and a certain BMI window? Or does it cover discontinuation of any GLP-1? Harith Rajagopalan: Right. So, we haven't yet finalized that, so I don't want to jump ahead. But I think it's reasonable to say that 15% was selected in our trial because we believe that, that would be a large enough weight loss to be able to discern a treatment effect. And we think that translates to Revita providing potential benefit in people who have achieved clinically meaningful weight loss on any GLP-1. Again, we use tirzepatide in the trial mainly for study homogeneity purposes, we believe that, that will not be a limitation on the label itself. Operator: Our next question comes from the line of Jason Gerberry of Bank of America Securities. Chi Meng Fong: This is Chi on for Jason. My first one is what are the remaining steps or gating factors, if any, for the U.S. filing in late 2026? Have you met with the FDA after the pivotal readout, the 6-month readout? Or would you need to meet with the FDA before the filing? And if that's the case, what are sort of discussions or feedback are you aiming to get at the meeting? Harith Rajagopalan: We have not met with the FDA. We've got a lot of feedback during the course of the year in interactive discussions because we are a breakthrough device. We do not anticipate any specific FDA feedback required beginning before our submission. We are working on compiling the elements of our submission right now. I think that the gating item will clearly be, I would say, that you can reasonably expect that -- when the second co-primary endpoint for REMAIN-1 will read out in the first quarter of 2027, those data will also be an important part of completing the clinical evidence package supporting our application. So while we've been preparing the design, the manufacturing, the other technical components of our de novo application for quite some time, our plan is to advance those components in the fourth quarter of this year. We are targeting the completion with the full clinical package in the first quarter of 2027. Chi Meng Fong: Got it. And my follow-up question is sort of maybe perhaps thinking about further down the line. As we step back, some of -- a couple of the observations you have made up from the data is that longer ablation length lead to better efficacy and also potentially bigger the weight loss prior to GLP-1 discontinuation, the better the efficacy. So as you think about further down the line, as there are potentially more novel GLP-1 therapies, maybe more potent therapies, what are the opportunities to sort of doing post-marketing studies to sort of reverse that Revita potential as the treatment landscape evolves? Harith Rajagopalan: Well, we actually think one of the interesting and underappreciated element of the story is that as the drug manufacturers get better at developing more potent agents that deliver more weight loss more rapidly, the need for an off-ramp actually only grows. Let's take some of the more recent drugs that are delivering even more profound weight loss than those that are already approved. We have clearly heard from clinical trial sites that when these studies end after patients have lost 40%, 45% of their body weight and then they no longer have access to the medicines. They are so hungry they are eating everything in their pantry. We've heard from 1 clinical investigator that they have had patients who've eaten their dog food and their cat food when they ran out of food in the pantry. Because when you lose that much weight and then the medicine is taken away from you, the body's physiologic drive to eat and regain weight is so profound. I believe the need for a manner to be able to blunt that regain is going to be even more important as the drugs get better. Operator: Our next question comes from the line of Chase Knickerbocker of Craig-Hallum. Chase Knickerbocker: Just one for me. Following the restructuring and the actions you've taken to extend runway, just trying to get a sense for how you're thinking about the initial go-to-market and how that thinking may have changed. Question being, kind of, how lean do you think you can be initially and still effectively target those first 50 to 100 potential centers of excellence, and whether you just want to discuss any update to how you're seeing commercial infrastructure kind of build? Or if you would be willing to discuss what you think it will cost in that first year, that would be great. Harith Rajagopalan: Yes. Thanks, Chase. We made substantial reductions to our workforce. It is true, but it's also important to understand that we've also fundamentally focused our company on the highest value activities as our needs have evolved. Number one, with the discontinuing our Rejuva program. Number two, as our clinical trial is coming to a close, the amount of money and effort spent on that is reducing. And then number three, as we have been finalizing our design and manufacturing models, a lot of the work required in order to be able to prepare that device to be able to launch has been completed. And so while we've made those changes and those changes have allowed us to reduce our spending and concentrating our resources that's what's allowed our operating cash spending to decline in the manner that it has. But we're not trying to execute the same operating plan with half the resources. We're just executing a much more focused plan. And when we think about commercialization, remember, we're not planning a broad highly resource-intensive launch from day 1. As we outlined at our September Investor Day, our strategy is to begin with a very targeted group of established bariatric and metabolic centers of excellence. They already have the patients, physicians and procedural infrastructure that Revita would need and that does give us the ongoing opportunity subject to authorization and reimbursement and financing to continue to be able to demonstrate early commercial adoption as we have already laid out. So we remain committed to being able to move towards the plan that we have laid out for you before. Operator: Our next question will be coming from the line of Jeffrey Cohen of Ladenburg Thalmann & Co. Jeffrey Cohen: Just one for me. I guess, Lara, you talked about the one-time severance for Q4. Could you give us a sense of SG&A versus R&D? And then give us also a sense of how the spend on SG&A and R&D plays out over the next few quarters? Lara Weber: Look, we haven't given any guidance actually on the split between SG&A and R&D. I would just say that we have reduced, as Harith said, we focused throughout the entire company and reprioritize, and the $2 million, it will be spread roughly in the same proportion that you could expect it to be with SG&A and R&D that we have today. And we'll give more information as we can. What we can say is that we have reduced our burn and expect it to come down to approximately 50% or $8 million by the end of Q2 2027. Operator: I will now turn the call back to Dr. Rajagopalan for closing remarks. Harith Rajagopalan: Thank you, everyone. Thank you to the shareholders who sent in questions for the first time. Three things to watch from here: Planned de novo submission; clarity on the CMS Rapid Rule; top line 12-month data from the REMAIN-1 pivotal cohort in the first quarter of 2027. We are funded through each of them. We look forward to updating you as we deliver. Thank you all. Operator: And this concludes today's conference call. Thank you for participating. You may now disconnect. Before you buy stock in Fractyl Health, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Fractyl Health wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $348,060!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,067,492!* Now, it's worth noting Stock Advisor's total average return is 849% — a market-crushing outperformance compared to 210% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors. See the 10 stocks » *Stock Advisor returns as of November 13, 2026. This article is a transcript of this conference call produced for The Motley Fool. While we strive for our Foolish Best, there may be errors, omissions, or inaccuracies in this transcript. As with all our articles, The Motley Fool does not assume any responsibility for your use of this content, and we strongly encourage you to do your own research, including listening to the call yourself and reading the company's SEC filings. Please see our Terms and Conditions for additional details, including our Obligatory Capitalized Disclaimers of Liability. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Fractyl Health (GUTS) Q3 2026 Earnings Call Transcript was originally published by The Motley Fool
Related articleQuarter not tagged2026-11-13Fractyl Health Inc (GUTS) Q3 2026 Earnings Call Highlights: Revita Hits Key Endpoint as ...
GuruFocus.com
Fractyl Health Inc (GUTS) Q3 2026 Earnings Call Highlights: Revita Hits Key Endpoint as ...
This article first appeared on GuruFocus. - R&D Expenses: $12.5 million in Q3 2026, down $5 million from $17.5 million in Q3 2025, driven by reduced Revita and Rejuva program spending and lower personnel costs. - SG&A Expenses: $6.2 million in Q3 2026, up $1 million from $5.2 million in Q3 2025, primarily due to higher personnel-related and stock compensation expenses. - Net Loss: $14.2 million in Q3 2026, compared with a net loss of $45.6 million in Q3 2025; the $31.5 million decrease driven by a $25.7 million favorable change in non-cash warrant liability fair value and a $4 million reduction in operating expenses. - Adjusted EBITDA: Negative $16 million in Q3 2026, compared with negative $20.8 million in Q3 2025, a $4.8 million improvement from reduced operating expenses excluding stock compensation. - Cash and Cash Equivalents: $31.5 million as of September 30, 2026. - Cash Used in Operations: Just below $16 million in Q3 2026, reflecting REMAIN-1 pivotal cohort spending and pre-reprioritization cost structure. - Operating Cash Spending Outlook: Expected to fall approximately 50% to roughly $8 million per quarter by the end of Q2 2027 as cost reductions take effect and pivotal expenditures decline. - Severance and Related Charges: Approximately $2 million expected, majority in Q4 2026, tied to ~45% workforce reduction. - Cash Runway: Sufficient to fund operations into Q2 2027, through the planned De Novo submission and anticipated 12-month REMAIN-1 top-line data. - Warning! GuruFocus has detected 2 Warning Signs with GUTS. - Is GUTS fairly valued? Test your thesis with our free DCF calculator. Release Date: November 12, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. - REMAIN-1 met its six-month co-primary endpoint with high statistical significance (p=0.0023), showing Revita patients retained ~80% of weight lost on tirzepatide. - Revita demonstrated a favorable safety profile with no device- or procedure-related serious adverse events, no deaths, and mostly mild events occurring on the day of procedure. - A dose-response relationship was observed, with longer ablation lengths (up to 20 cm) associated with greater weight loss maintenance and no additional safety signals. - Fractyl Health Inc (NASDAQ:GUTS) implemented a restructuring to cut quarterly operating cash spending by ~50% to ~$8 million b…Read full documentShow less
This article first appeared on GuruFocus. - R&D Expenses: $12.5 million in Q3 2026, down $5 million from $17.5 million in Q3 2025, driven by reduced Revita and Rejuva program spending and lower personnel costs. - SG&A Expenses: $6.2 million in Q3 2026, up $1 million from $5.2 million in Q3 2025, primarily due to higher personnel-related and stock compensation expenses. - Net Loss: $14.2 million in Q3 2026, compared with a net loss of $45.6 million in Q3 2025; the $31.5 million decrease driven by a $25.7 million favorable change in non-cash warrant liability fair value and a $4 million reduction in operating expenses. - Adjusted EBITDA: Negative $16 million in Q3 2026, compared with negative $20.8 million in Q3 2025, a $4.8 million improvement from reduced operating expenses excluding stock compensation. - Cash and Cash Equivalents: $31.5 million as of September 30, 2026. - Cash Used in Operations: Just below $16 million in Q3 2026, reflecting REMAIN-1 pivotal cohort spending and pre-reprioritization cost structure. - Operating Cash Spending Outlook: Expected to fall approximately 50% to roughly $8 million per quarter by the end of Q2 2027 as cost reductions take effect and pivotal expenditures decline. - Severance and Related Charges: Approximately $2 million expected, majority in Q4 2026, tied to ~45% workforce reduction. - Cash Runway: Sufficient to fund operations into Q2 2027, through the planned De Novo submission and anticipated 12-month REMAIN-1 top-line data. - Warning! GuruFocus has detected 2 Warning Signs with GUTS. - Is GUTS fairly valued? Test your thesis with our free DCF calculator. Release Date: November 12, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. - REMAIN-1 met its six-month co-primary endpoint with high statistical significance (p=0.0023), showing Revita patients retained ~80% of weight lost on tirzepatide. - Revita demonstrated a favorable safety profile with no device- or procedure-related serious adverse events, no deaths, and mostly mild events occurring on the day of procedure. - A dose-response relationship was observed, with longer ablation lengths (up to 20 cm) associated with greater weight loss maintenance and no additional safety signals. - Fractyl Health Inc (NASDAQ:GUTS) implemented a restructuring to cut quarterly operating cash spending by ~50% to ~$8 million by Q2 2027, extending cash runway into Q2 2027 through key milestones. - Reimbursement pathway is advancing: a dedicated CPT Category III code (1122T) effective January 1, 2027, and CMS RAPID coverage pathway with strong stakeholder support could improve coverage. - Fractyl Health Inc (NASDAQ:GUTS) reduced its workforce by ~45% and discontinued internal development of its Rejuva gene therapy program, which may limit long-term pipeline diversity. - The company will need additional capital beyond Q2 2027 to bring Revita to market, creating financing risk. - The 12-month co-primary endpoint and key secondary data are not expected until Q1 2027, leaving a gap in evidence for the full regulatory package. - Uncertainty remains around CMS RAPID on-ramp inclusion for devices like Revita, with a decision expected by early January 2027. - The FDA has not yet met with Fractyl Health Inc (NASDAQ:GUTS) regarding the De Novo submission, and final indication statement and labeling are not yet finalized. Q: What concrete steps are the board and management taking to restore credibility with investors, including institutional investors? A: CEO Harith Rajagopalan pointed to four steps: (1) the data REMAIN-1 met its six-month co-primary endpoint in a randomized, double-blinded, sham-controlled study with high statistical significance; (2) discipline the October decision to focus entirely on Revita and cut quarterly operating cash spending by roughly half; (3) governance adding Mike Wartell as an independent director; and (4) continuous dialogue with institutional and retail investors. He said the company expects to be judged on execution: the De Novo submission, 12-month data, and clarity on RAPID. Q: How does the company plan to fund its upcoming milestones, and is it exploring strategic partnerships, licensing agreements, or a potential acquisition? A: CFO Lara Weber said the $31.5 million in cash and cash equivalents at September 30, 2026 is sufficient to fund operations into the second quarter of 2027, through the planned De Novo submission and the 12-month REMAIN-1 data, with quarterly operating cash spending expected to fall roughly 50% to about $8 million by the end of Q2 2027. Beyond those milestones, additional capital will be needed to bring Revita to market, and the company will weigh every option with shareholder value in mind. She declined to comment on specific strategic discussions, noting every milestone delivered potentially expands the company's options. Q: What are the remaining steps or gating factors for the US De Novo filing in late 2026, and has the company met with the FDA since the six-month pivotal readout? A: CEO Harith Rajagopalan said the company has not met with the FDA and does not anticipate needing specific FDA feedback before beginning the submission, having received extensive interactive feedback during the year as a Breakthrough Device. The company is compiling the design, manufacturing, and technical components of the application in Q4 2026, with the 12-month co-primary endpoint data in Q1 2027 expected to be an important part of completing the clinical evidence package. Completion of the full submission is targeted for Q1 2027. Q: How do you expect the FDA to treat the possibly device- or procedure-related serious adverse events (GI hemorrhage and acute blood loss anemia) when determining Revita's device classification? A: CEO Harith Rajagopalan said he cannot speak for the FDA but noted the single patient was on two contraindicated non-steroidal anti-inflammatory drugs simultaneously for an unrelated indication, and two endoscopies during the bleeding episode found no bleeding source in the duodenum and required no intervention. He said the event was classified as "possibly related" only because the patient was in the study, and he does not believe it will change anyone's perception of Revita's safety profile. Q: What indication statement are you proposing is it tied to prior weight loss of at least 15% and a certain BMI window, or does it cover discontinuation of any GLP-1? A: CEO Harith Rajagopalan said the indication has not been finalized. The 15% threshold was selected for the trial because it represents a large enough weight loss to discern a treatment effect, and he believes it translates to potential benefit for people who have achieved clinically meaningful weight loss on any GLP-1. Tirzepatide was used in the trial mainly for study homogeneity and should not be a limitation on the label itself. Q: Given the better results with longer ablations, what training or procedural steps will ensure patients in real-world practice consistently receive a full-length treatment of 20 centimeters or more? A: CEO Harith Rajagopalan said post-hoc analyses showed the greatest effect in patients reaching 20 centimeters, with no associated safety signal, and physicians in REMAIN-1 reached that length with the current device. Each additional 2 centimeters takes about two minutes, and the findings will inform the procedural parameters proposed to the FDA and, if Revita is approved, the physician training program for launch. Q: Since longer ablations produced greater efficacy, do you expect physicians to require longer training than previously estimated? A: CEO Harith Rajagopalan said longer ablation lengths were associated with greater reduction in weight regain in exploratory analyses, and he believes physicians can and will be trained to deliver those treatments consistently. Each additional 2 centimeters adds roughly two minutes to the procedure, so this is about optimizing the extent of treatment within a standardized endoscopic procedure rather than a fundamentally different skill set. Physicians improved their ability to deliver longer treatments with experience, and no safety signal has been observed with longer ablations. Q: What proportion of patients at the top high-volume accredited metabolic and bariatric centers are currently Medicare patients, given the GLP-1 Bridge Program ends at the end of 2027? A: CEO Harith Rajagopalan said the early launch is predicated on Medicare patients, though until about six months ago relatively few patients were Medicare patients. Every center in dialogue is seeing a rapid increase in Medicare patients seeking GLP-1s through the bridge program. He cited Eli Lilly CEO David Ricks' comment that 700,000 patients had joined the program, versus an expected 4 million to 5 million by around this time next year a meaningful addition to the roughly 30 million people on GLP-1s today. Q: Following the restructuring, how lean can the initial go-to-market be while still effectively targeting the first 50 to 100 centers of excellence, and what might the first year cost? A: CEO Harith Rajagopalan said the company is not trying to execute the same operating plan with half the resources but a much more focused one, with savings from discontinuing Rejuva, winding down trial spending, and completed design and manufacturing work. The launch will not be broad or highly resource-intensive from day one; it begins with a targeted group of established bariatric and metabolic centers of excellence that already have the patients, physicians, and procedural infrastructure, with the opportunity to demonstrate early commercial adoption subject to authorization, reimbursement, and financing. Q: How will the one-time Q4 severance be split between SG&A and R&D, and how will spending in each play out over the next few quarters? A: CFO Lara Weber said the company has not given guidance on the SG&A/R&D split, but the approximately $2 million in severance and related charges will be For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Related articleQuarter not tagged2026-11-12Fractyl Health Reports Third Quarter 2026 Financial Results and Business Updates
GlobeNewswire
Fractyl Health Reports Third Quarter 2026 Financial Results and Business Updates
REMAIN-1 Pivotal Cohort met its six-month co-primary endpoint with high statistical significance (p=0.0023); Revita® participants retained approximately 80% of GLP-1-induced weight loss versus 67% for sham Planned FDA De Novo submission in late Q4 2026; topline 12-month data from the REMAIN-1 Pivotal Cohort anticipated in Q1 2027 Sharpened focus on Revita, with a workforce reduction of approximately 45% and discontinuation of internal Rejuva development Cash runway into Q2 2027, through planned De Novo submission and anticipated 12-month pivotal data; quarterly operating cash spending expected to be reduced by approximately 50%, to approximately $8 million, by the end of Q2 2027 Conference call today at 4:30 p.m. ET BURLINGTON, Mass., Nov. 12, 2026 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the Company or Fractyl), a clinical-stage metabolic therapeutics company focused on pioneering novel approaches to treat obesity and type 2 diabetes (T2D), today announced third quarter 2026 financial results and provided business updates. The Company also reiterated its anticipated Revita® milestones, including a planned U.S. Food and Drug Administration (FDA) De Novo marketing application submission in late Q4 2026 and topline 12-month data from the REMAIN-1 Pivotal Cohort in Q1 2027, and its cash runway guidance into Q2 2027. "There are approximately 1 million Americans discontinuing GLP-1s each month, and these individuals are at high risk of weight and metabolic rebound. In this context, we believe the positive pivotal results from REMAIN-1 represent a defining moment for Fractyl. In the most rigorous stress test we could conceive, a single Revita procedure met its six-month co-primary endpoint with high statistical significance," said Harith Rajagopalan, M.D., Ph.D., Co-Founder, President and Chief Executive Officer of Fractyl. "Armed with positive data, we have focused the Company around Revita's post-GLP-1 weight maintenance opportunity. We expect the capital we have today to be sufficient to fund our planned De Novo submission and upcoming 12-month pivotal data and. Our goal is for Revita to potentially establish an entirely new therapeutic category of post-GLP-1 weight maintenance by aiming to reverse years of diet-induced damage to the gut." Select Recent Revita Clinical Highlights Fractyl is studying Revita in the REMAIN-1 weight maintenance prog…Read full documentShow less
REMAIN-1 Pivotal Cohort met its six-month co-primary endpoint with high statistical significance (p=0.0023); Revita® participants retained approximately 80% of GLP-1-induced weight loss versus 67% for sham Planned FDA De Novo submission in late Q4 2026; topline 12-month data from the REMAIN-1 Pivotal Cohort anticipated in Q1 2027 Sharpened focus on Revita, with a workforce reduction of approximately 45% and discontinuation of internal Rejuva development Cash runway into Q2 2027, through planned De Novo submission and anticipated 12-month pivotal data; quarterly operating cash spending expected to be reduced by approximately 50%, to approximately $8 million, by the end of Q2 2027 Conference call today at 4:30 p.m. ET BURLINGTON, Mass., Nov. 12, 2026 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the Company or Fractyl), a clinical-stage metabolic therapeutics company focused on pioneering novel approaches to treat obesity and type 2 diabetes (T2D), today announced third quarter 2026 financial results and provided business updates. The Company also reiterated its anticipated Revita® milestones, including a planned U.S. Food and Drug Administration (FDA) De Novo marketing application submission in late Q4 2026 and topline 12-month data from the REMAIN-1 Pivotal Cohort in Q1 2027, and its cash runway guidance into Q2 2027. "There are approximately 1 million Americans discontinuing GLP-1s each month, and these individuals are at high risk of weight and metabolic rebound. In this context, we believe the positive pivotal results from REMAIN-1 represent a defining moment for Fractyl. In the most rigorous stress test we could conceive, a single Revita procedure met its six-month co-primary endpoint with high statistical significance," said Harith Rajagopalan, M.D., Ph.D., Co-Founder, President and Chief Executive Officer of Fractyl. "Armed with positive data, we have focused the Company around Revita's post-GLP-1 weight maintenance opportunity. We expect the capital we have today to be sufficient to fund our planned De Novo submission and upcoming 12-month pivotal data and. Our goal is for Revita to potentially establish an entirely new therapeutic category of post-GLP-1 weight maintenance by aiming to reverse years of diet-induced damage to the gut." Select Recent Revita Clinical Highlights Fractyl is studying Revita in the REMAIN-1 weight maintenance program, which is designed to evaluate Revita's potential to maintain weight loss following GLP-1 based therapy discontinuation. The REMAIN-1 program includes three distinct participant cohorts that are conducted under a single IDE: the REVEAL-1 Cohort, the REMAIN-1 Midpoint Cohort and the REMAIN-1 Pivotal Cohort. - In October 2026, Fractyl reported positive topline six-month results from the REMAIN-1 Pivotal Cohort, a 308-participant, multicenter, randomized, double-blind, sham-controlled study of Revita for weight maintenance in adults with obesity following discontinuation of GLP-1 therapy. REMAIN-1 met its pre-specified six-month co-primary endpoint of weight loss retention, as patients treated with a single Revita procedure demonstrated a highly statistically significant reduction in weight regain compared to sham (p=0.0023). - Six-month co-primary endpoint met: In the modified intention-to-treat (mITT) population (N=308), Revita participants maintained approximately 80% of their GLP-1-induced weight loss after a single treatment at six months with high statistical significance versus sham (p=0.0023). 32% of Revita participants were either weight stable or had further weight loss at six months post GLP-1 discontinuation (<2% regain or incremental loss) versus 18% for sham (post hoc; nominal p=0.020). - Dose-dependent effect observed: In a post hoc analysis by ablation length, participants who received 12 to 18 cm of duodenal ablation had 43% less regain than sham (observed mean weight regain of 4.7% versus 8.2%; n=107 versus 74). Participants who received 20 cm or more had 53% less regain than sham (mean regain of 3.8%; n=47). - Treatment effect grew over time: The difference in weight regain between Revita and sham widened at each assessment, nearly doubling from Month 3 to Month 6. - Favorable interim safety data: There have been no device- or procedure-related serious adverse events, no deaths, and no unanticipated adverse device effects observed as of the September 24, 2026, data cut-off date. Related adverse events were predominantly mild and peri-procedural, with 94% occurring within seven days of the procedure. - The second co-primary endpoint, the proportion of Revita participants maintaining at least 5% total body weight loss relative to their pre-tirzepatide weight at one year, will be assessed against an FDA-mandated pre-specified performance goal of greater than 50%. Commercial Readiness and Market Access - In September 2026, Fractyl hosted a Commercial Investor Day outlining the potential path to commercializing Revita in post-GLP-1 weight maintenance. The Company's launch plan focuses on the top 100 to 200 of approximately 1,000 accredited bariatric centers in the United States, beginning with 30 to 50 centers in the first year. - In October 2026, the American Medical Association published Category III CPT code 1122T, a dedicated code for the Revita procedure, which takes effect January 1, 2027, well ahead of a potential U.S. launch in early 2028. - The Centers for Medicare & Medicaid Services (CMS) has proposed RAPID, a pathway that could align Medicare coverage with FDA authorization for breakthrough devices. More than 160 comments were filed during the comment period, nearly all supporting an on-ramp for devices with pivotal trials already underway, including comments from ASGE and ASMBS that cited Revita. Fractyl expects to learn whether CMS adopts such an on-ramp in early January 2027. - In October 2026, Fractyl announced findings from company-sponsored market research highlighting strong patient interest in a one-time procedural approach to weight maintenance following GLP-1 therapy. Among nearly 300 current or recent GLP-1 users surveyed, 33% preferred stopping GLP-1 therapy and receiving a hypothetical endoscopic procedure. - In October 2026, Fractyl announced additions to its U.S. patent portfolio for Revita. The U.S. Patent and Trademark Office issued U.S. Patent No. 12,740,821, covering features of the Revita single-use catheter, with a term extending to November 28, 2042, and issued a Notice of Allowance for a patent application directed to Revita's thermal dosing method. Fractyl's intellectual property portfolio includes 39 granted U.S. patents, approximately 40 pending U.S. applications and more than 50 issued patents outside the United States. Sharpened Focus on Revita On October 21, 2026, Fractyl adopted a plan to sharpen its strategic focus on its Revita program in connection with a strategic reprioritization, concentrating its financial and operational resources on advancing Revita toward potential FDA marketing authorization and commercialization in post-GLP-1 weight maintenance. - Workforce Reduction: The Company is reducing its workforce by approximately 45%, with the reduction expected to be completed during the fourth quarter of 2026. The Company estimates that it will incur charges of approximately $2 million for severance and other employee termination-related costs, with the majority of such costs to be incurred in the fourth quarter of 2026. - Reduced Quarterly Operating Cash Spending: As cost reductions take effect and REMAIN-1 Pivotal Cohort expenditures decline, the Company expects quarterly operating cash spending to be reduced by approximately 50%, to approximately $8 million, by the end of Q2 2027. - Rejuva Strategic Alternatives: The Company is discontinuing internal development of its Rejuva gene therapy program and is seeking strategic alternatives to maximize the value of the program. There can be no assurance that the Company's review of strategic alternatives for Rejuva will result in any transaction, and the Company does not intend to disclose further developments unless and until it determines that disclosure is appropriate or required. Appointment of Michael Wartell as Independent Director - On November 6, 2026, the Company announced that effective November 2, 2026, the Board of Directors (the "Board") increased the size of the Board from nine to ten and appointed Michael Wartell as a Class III director, with a term expiring at the Company's 2027 annual meeting of stockholders and until his successor is duly elected and qualified or until his earlier resignation or removal. Mr. Wartell is the President of Bluerose Associates LLC and has extensive experience serving as an independent director for both public and private corporations, specializing in guiding companies through complex situations. Fractyl Forward: Advancing Revita Toward a New Therapeutic Category in Obesity Care The Company continues to anticipate the following milestones: - Late Q4 2026: Planned FDA De Novo submission for Revita in post-GLP-1 weight maintenance. - January 1, 2027: Category III CPT code 1122T for the Revita procedure takes effect. - Q1 2027: Anticipated topline 12-month data from the REMAIN-1 Pivotal Cohort, including the second co-primary endpoint. - Late 2027: Potential FDA marketing authorization. - Early 2028: Potential U.S. commercial launch. As in all applications, the FDA indicated that final pathway determinations will be made following review of the complete safety dataset, which the Company intends to include in its potential De Novo submission. Third Quarter 2026 Financial Results - Research and Development Expenses: R&D expenses were $12.5 million for the quarter ended September 30, 2026, compared to $17.5 million for the same period in 2025. The decrease of $5.0 million was primarily related to reduced spending on Fractyl's Revita and Rejuva programs, as well as lower personnel-related expenses. - Selling, General and Administrative Expenses: SG&A expenses were $6.2 million for the quarter ended September 30, 2026, compared to $5.2 million for the same period in 2025. The increase of $1.0 million was primarily driven by higher personnel-related expenses and stock compensation expenses, partially offset by decreased professional service fees. - Net Loss: For the quarter ended September 30, 2026, Fractyl reported a net loss of $14.2 million, compared to a net loss of $45.6 million for the same period in 2025. The decrease in net loss of $31.5 million was driven by a $4.0 million reduction in operating expenses, a $25.7 million favorable non-cash change in the fair value of warrant liabilities, $1.6 million lower non-cash loss from change in fair value of debt, and $0.1 million higher interest income. - Adjusted EBITDA: Adjusted EBITDA was negative $16.0 million for the quarter ended September 30, 2026, compared to negative $20.8 million for the same period in 2025. The decrease in the non-GAAP adjusted loss of $4.8 million was primarily due to reduced operating expenses excluding stock compensation expenses. - Cash Position: As of September 30, 2026, Fractyl had approximately $31.5 million in cash and cash equivalents. Based on current business plans, the Company believes its cash position will fund operations into the second quarter of 2027, through the planned De Novo submission and anticipated 12-month REMAIN-1 Pivotal Cohort data, subject to compliance with the minimum liquidity covenant under the Company's credit agreement, as discussed further in the "Liquidity and Capital Resources" section of our Quarterly Report on Form 10-Q. Webcast and Conference Call Information Fractyl will host a conference call to discuss its third quarter financial results and provide business updates on Thursday, November 12, 2026, at 4:30 p.m. ET. A live webcast of the conference call can be accessed in the "Events" section of Fractyl's website at ir.fractyl.com. The webcast will be archived and available for replay for at least 30 days after the event. Ahead of the call, Fractyl invited all shareholders to submit and vote on questions for management through Say by Robinhood by visiting: https://app.saytechnologies.com/fractyl-health-2026-q3. Management will address a selection of the most-voted shareholder questions during the call. About Fractyl Health Fractyl is a clinical-stage metabolic therapeutics company focused on pioneering novel approaches to treat obesity and type 2 diabetes. The Company's lead product candidate, Revita, is an endoscopic procedural therapy in pivotal development for post-GLP-1 weight maintenance. Fractyl's goal is to change the course of metabolic disease, advancing treatment from chronic management toward prevention and reversal of disease. Fractyl is headquartered in Burlington, Massachusetts. About Revita The Revita® DMR System is Fractyl's lead product candidate, designed to remodel the duodenal lining via a single, minimally invasive endoscopic procedure intended to restore healthy nutrient sensing and signaling disrupted by chronic metabolic disease. By targeting duodenal dysfunction, Revita is designed to address an underlying driver of obesity and enable durable weight maintenance following GLP-1 discontinuation. Revita has received FDA Breakthrough Device Designation for weight maintenance in people with obesity who discontinue GLP-1 therapies. Revita is for investigational use only in the United States and is CE marked in the European Union and United Kingdom. Non-GAAP Financial Measures This press release contains certain financial information that is not presented in conformity with U.S. generally accepted accounting principles (GAAP), including Adjusted EBITDA, which is a non-GAAP financial measure as defined in Regulation G promulgated under the Securities Exchange Act of 1934. This non-GAAP financial measure is provided as supplemental information to Fractyl's financial measures presented in this press release in accordance with GAAP. The Company defines Adjusted EBITDA as net loss adjusted to exclude (i) interest income, net, (ii) depreciation expense, (iii) stock-based compensation expense, (iv) change in fair value of notes payable and (v) change in fair value of warrant liabilities. Management believes Adjusted EBITDA provides useful supplemental information to investors regarding the Company's core operating performance and facilitates period-to-period comparisons by excluding items that are non-cash or non-operational in nature and may vary in magnitude. Adjusted EBITDA is also used by management in evaluating the Company's operating performance and in planning and forecasting activities. The non-GAAP financial measures used by Fractyl may not be the same or calculated in the same manner as those used and calculated by other companies. Non-GAAP financial measures have limitations as analytical tools and should not be considered in isolation or as a substitute for Fractyl's financial results prepared and reported in accordance with GAAP. This non-GAAP measure should not be construed as an inference that the Company's future results will be unaffected by unusual or non-recurring items. A reconciliation of Adjusted EBITDA reported in this press release to the most comparable GAAP measure for the respective periods appears in the table captioned "Reconciliation of GAAP Net Loss to Adjusted EBITDA" later in this press release. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact are forward-looking statements. These statements may be identified by words such as "aims," "anticipates," "believes," "could," "estimates," "expects," "forecasts," "goal," "intends," "may," "plans," "possible," "potential," "seeks," "will" and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, without limitation, statements regarding: the potential benefits of Fractyl's sharpened strategic focus and reprioritization, including the workforce reduction and its anticipated impact on Fractyl's expenditures and financial runway; Fractyl's anticipated financial performance, including cash and cash equivalents, for any period of time; Fractyl's expected quarterly operating cash spending and cash runway, including the period over which its existing cash and cash equivalents will be sufficient to satisfy the minimum liquidity covenant under its credit agreement; Fractyl's ability to continue as a going concern; the promise and potential impact of Fractyl's clinical trial data and product candidates, including Revita's potential for maintaining weight loss after GLP-1 based therapy discontinuation; the design, initiation, timing and results of clinical studies or readouts, including readouts from the REMAIN-1 Pivotal Cohort, including anticipated 12-month data from the REMAIN-1 Pivotal Cohort and the second co-primary endpoint; the potential launch or commercialization of any of Fractyl's product candidates or products; Fractyl's commercial readiness activities and launch plans; coding, coverage and payment for Revita, including the effectiveness and use of Category III CPT code 1122T, the timing and outcome of any CMS rulemaking, including RAPID, and eligibility for or timing of Medicare transitional pass-through payment or other coverage, which are subject to AMA and CMS review and are not assured; Fractyl's regulatory strategy, including the timing of any potential De Novo marketing application submission and the potential use and benefits of the De Novo pathway (FDA pre-submission feedback is advisory and non-binding, and there is no assurance that FDA will accept a De Novo marketing application submission or that the Revita DMR System will receive marketing authorization, or as to the timing of any such authorization); the potential treatment population or benefits for any of Fractyl's product candidates or products; Fractyl's exploration of strategic alternatives for Rejuva and the potential benefits thereof; Fractyl's strategic and product development objectives and goals; and the timing of any of the foregoing. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause Fractyl's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the risks that are discussed more fully in Fractyl's filings with the Securities and Exchange Commission (the SEC) including the "Risk Factors" section of Fractyl's Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 24, 2026, and other documents Fractyl subsequently files with or furnishes to the SEC, including Fractyl's Quarterly Report on Form 10-Q for the quarter ended September 30, 2026, filed with the SEC on November 12, 2026. These forward-looking statements are based on management's current estimates and expectations. While Fractyl may elect to update such forward-looking statements at some point in the future, Fractyl disclaims any obligation to do so, even if subsequent events cause Fractyl's views to change. Contact Brian Luque, Head of Investor Relations and Corporate Development [email protected], 951.206.1200 Fractyl Health, Inc. Selected Consolidated Balance Sheet Data (in thousands) (unaudited) | September 30, 2026 | | | December 31, 2025 | Cash and cash equivalents | $ | 31,515 | | | $ | 81,540 | Restricted cash | | 4,255 | | | | 4,255 | Working capital (1) | | 16,989 | | | | 69,247 | Total assets | | 65,925 | | | | 121,402 | Notes payable, long-term | | 29,234 | | | | 30,586 | Total liabilities | | 79,141 | | | | 111,944 | Total stockholders' equity (deficit) | | (13,216 | ) | | | 9,458 | (1) Working capital is defined as total current assets less total current liabilities. Fractyl Health, Inc. Consolidated Statements of Operations and Comprehensive Loss (in thousands, except for share and per share information) (unaudited) | Three Months Ended September 30, | | | Nine Months Ended September 30, | | 2026 | | | 2025 | | | 2026 | | | 2025 | Operating expenses: | | | | | | | | | | | Research and development | $ | 12,454 | | | $ | 17,457 | | | $ | 41,864 | | | $ | 58,043 | Selling, general and administrative | | 6,195 | | | | 5,237 | | | | 16,701 | | | | 15,489 | Total operating expenses | | 18,649 | | | | 22,694 | | | | 58,565 | | | | 73,532 | Loss from operations | | (18,649 | ) | | | (22,694 | ) | | | (58,565 | ) | | | (73,532 | ) Other income (expense), net: | | | | | | | | | | | Interest income, net | | 297 | | | | 166 | | | | 1,321 | | | | 895 | Change in fair value of notes payable | | (284 | ) | | | (1,868 | ) | | | (2,276 | ) | | | (3,824 | ) Change in fair value of warrant liabilities | | 4,499 | | | | (21,201 | ) | | | 29,070 | | | | (20,724 | ) Other expense, net | | (13 | ) | | | (6 | ) | | | (20 | ) | | | (42 | ) Total other income (expense), net | | 4,499 | | | | (22,909 | ) | | | 28,095 | | | | (23,695 | ) Net loss and comprehensive loss | $ | (14,150 | ) | | $ | (45,603 | ) | | $ | (30,470 | ) | | $ | (97,227 | ) Net loss per share, basic and diluted (2) | $ | (1.07 | ) | | $ | (8.46 | ) | | $ | (2.30 | ) | | $ | (21.51 | ) Weighted-average number of common shares outstanding, basic and diluted (2) | | 13,250,080 | | | | 5,387,747 | | | | 13,226,323 | | | | 4,520,293 | (2) All share and per share information has been retroactively adjusted to reflect the 1-for-12 reverse stock split effected on October 2, 2026. Refer to Quarterly Report on Form 10-Q for details. Fractyl Health, Inc. Reconciliation of GAAP Net Loss to Adjusted EBITDA (in thousands) (unaudited) | Three Months Ended September 30, | | | Nine Months Ended September 30, | | 2026 | | | 2025 | | | 2026 | | | 2025 | Net loss | $ | (14,150 | ) | | $ | (45,603 | ) | | $ | (30,470 | ) | | $ | (97,227 | ) Interest income, net | | (297 | ) | | | (166 | ) | | | (1,321 | ) | | | (895 | ) Depreciation | | 276 | | | | 290 | | | | 835 | | | | 850 | EBITDA | | (14,171 | ) | | | (45,479 | ) | | | (30,956 | ) | | | (97,272 | ) Stock-based compensation expense | | 2,386 | | | | 1,638 | | | | 7,413 | | | | 4,829 | Change in fair value of notes payable | | 284 | | | | 1,868 | | | | 2,276 | | | | 3,824 | Change in fair value of warrant liabilities | | (4,499 | ) | | | 21,201 | | | | (29,070 | ) | | | 20,724 | Adjusted EBITDA | $ | (16,000 | ) | | $ | (20,772 | ) | | $ | (50,337 | ) | | $ | (67,895 | )
TranscriptFY2026 Q32026-11-12FY2026 Q3 earnings call transcript
Earnings source - 70 paragraphs
FY2026 Q3 earnings call transcript
Good afternoon, and welcome to the Fractyl Health Third Quarter 2026 Financial Results and Business Update Call. As a reminder, this conference call is being recorded. At this time, all participants are in a listen-only mode. There will be a question-and-answer session following management's prepared remarks. I will now turn the call over to Brian Luque, Head of Investor Relations and Corporate Development at Fractyl. Brian, you may begin.
Thank you. This afternoon, we issued a press release that outlines the topics we plan to discuss today. This release is available at www.fractyl.com under the Investors tab. Joining us on the call today are Dr. Harith Rajagopalan, Chief Executive Officer, and Lara Smith Weber, Chief Financial Officer. Before we begin, one change to our format. For the first time, we invited all of our shareholders to submit and vote on questions for management through Say by Robinhood. After our prepared remarks, I will read a selection of the most voted shareholder questions, and then the operator will open the line to our covering analysts. Thank you to everyone who took part. During this call, we make forward-looking statements, which involve risks and uncertainties that may cause actual results to differ materially from our forward-looking statements.
We provide a comprehensive list of risk factors in our SEC filings, including the quarterly report on Form 10-Q filed today, which I encourage you to review. Any forward-looking statements on the call are subject to substantial risks and uncertainties, speak only as of the call's original date, and we undertake no obligation to update or revise any of the statements, even if subsequent events cause the company's views to change. It is now my pleasure to pass the call over to Harith.
Thank you, Brian. Good afternoon, everyone. Nearly 30 million Americans are now on GLP-1 therapy. Approximately 1 million are discontinuing GLP-1s each month. Yet, those who take GLP-1s, only one in 12 Americans remain on them for obesity at the end of three years. What happens for the 11 out of 12 who stop? On average, 85% of patients regain weight, and roughly two-thirds of the weight comes back within a year. That is a systemic pattern driven by biology, not an individual failure of willpower, and it doesn't have to be this way. Why does the weight come back? We believe the answer is in the gut. Modern unhealthy diets accelerate cellular aging in the gut. In plain terms, those changes make us more prone to obesity, and the aging gut may retain a metabolic memory that perpetuates disease.
GLP-1 medicines have proven that dramatic weight loss is possible, but they neither reverse the underlying cellular aging causing obesity nor regenerate a healthy gut. They leave the underlying problem untouched. Revita aims to do both. It is designed to reset the gut's metabolic memory as a one-time outpatient procedure designed to ablate the damaged, unhealthy lining of the duodenum to allow healthier tissue to regenerate in its place. LASIK for obesity. It means the gut is now working with, not against, a patient's weight loss program. This means the potential for better overall health and weight loss that can actually last even after the drugs are stopped. Last month, we put that idea through the most rigorous stress test we could conceive, REMAIN-1, in which patients were driven to achieve rapid and profound weight loss and then stopped high-dose tirzepatide outright.
It's the most extreme example of what could happen in the real world, and the study met its six-month co-primary endpoint with high statistical significance. Today, I want to take you through three things. Number one, what the REMAIN-1 top line showed, why we believe it is clinically meaningful, and what to expect next as we look to complete the study in Q1 2027. Number two, why the market is ready for Revita. Number three, how we have rebuilt Fractyl around it. Then Lara will take you through the quarter. I will close on three milestones in front of us: submitting our De Novo marketing application later this quarter, 12-month co-primary and key secondary endpoints in the first quarter of 2027, and clarity on the CMS RAPID reimbursement rule. All value-accretive milestones funded with the cash we have on hand. Let me take each in turn.
What did REMAIN-1 top line show? We designed REMAIN-1 to provide a rapid and clean assessment of Revita safety and efficacy in the post-GLP-1 weight maintenance setting. Adults with obesity who had never taken a GLP-1 started tirzepatide, stayed on it until they had lost at least 15% of their body weight. On average, they lost 18.3% over about 25 weeks, and about half reached the maximum 15 milligram dose. The drug was stopped, and participants were randomized two to one to Revita or to a sham procedure, double-blind. 308 participants make up the modified intention-to-treat population. The study met its six-month co-primary endpoint with high statistical significance, P-value of 0.0023.
Revita participants kept about 80% of the weight they had lost on the tirzepatide, and whichever way we analyze it across primary and every pre-specified sensitivity analysis, the result was highly statistically significant with two to three zeros in the P-value. If anything, we believe the comparison with sham is conservative. Sham participants were about three times as likely as Revita participants to restart an anti-obesity medication, which potentially masks the true effect of Revita. Two findings I want you to remember. First, the effect grew over time. The gap between Revita and sham widened at every visit from month one to three to six, and nearly doubled between months three and six. In our pilot, Revita patients leveled off at about 80% of their weight loss retained at one year, and so far, the pivotal is tracking that experience. Second, what this means for an individual patient.
One in three Revita participants were weight stable or had lost more weight six months after stopping tirzepatide. Nearly half kept at least 80% of their weight loss. When we apply the method for our 12-month responder endpoint at six months as a post-hoc analysis, more than 97% of Revita participants maintained clinically meaningful weight loss at one year against a performance goal of greater than 50%. The formal test of that second co-primary endpoint will come with our 12-month data in the first quarter of 2027. We also continue to see a dose response with ablation length. In our pilot, the benefit was clearest above 14 centimeters. With a much larger study, we now have the numbers and granularity to see it more precisely.
In a post-hoc analysis, separation from sham begins at a dose as low as 12 centimeters and progressively better with a longer ablation for the full length of the duodenum, or roughly 20 centimeters. Our best performing patients received a full treatment of 20 centimeters or more, and they achieved less than half the regain of sham. REMAIN-1 contributes not only the evidence to support our planned De Novo submission later this quarter, but also the evidence to inform how to train physicians to perform the procedure after approval for maximum effect. Each additional two centimeters takes about two minutes, and physicians lengthen their ablations as they gained experience in the study. With the six-month and 12-month data, we will have adequate information to define the appropriate treatment length for real-world implementation. There is an added benefit to the dose response we are observing.
Given the novelty of the duodenum as a target, dose response builds credibility in target validation, something we are hearing from physicians over and over again. On safety, the profile was what we have come to expect from Revita. There were no device or procedure-related serious adverse events, no deaths, no unanticipated adverse device effects. Related events were mostly mild, and the vast majority of them occurred only on the day of the procedure. The next clinical milestone for REMAIN-1 is clear. In the first quarter of 2027, we expect top-line 12-month data from the second co-primary endpoint. If both co-primary endpoints are met, our key secondary endpoints, including complete ablation and higher run-in weight loss, will then be formally tested in sequence. Here is what success looks like at 12 months. First, we meet the second co-primary endpoint, which is the pre-specified performance goal.
Based on what we see at six months, we are highly confident in that result. Second, at longer ablation lengths, we want to see even greater effects as we showed at six months. We hope to see the Revita arm with a complete treatment maintain a majority of its weight loss at one year. The physicians we have been talking to and our patient market research tells us that a full ablation should be the expected standard procedure for Revita if it is authorized. Now let us step out of the data and into the doctor's office. In a consumer market, physicians will not talk to patients about placebo-adjusted differences. They will say, "Here is what you can expect to keep." REMAIN-1 top line clearly demonstrated that patients have the potential to retain the majority of their hard-won weight loss with a low risk of serious side effects.
Now let's turn to why the market is ready for Revita. At our commercial strategy day in September, we laid out why we see Revita's launch as market activation, not market creation. Our commercial model is a targeted and efficient launch at bariatric and metabolic centers of excellence. The patients, the interventional physicians and surgeons, the procedure rooms, and the payer precedent already exist. What is missing is a durable off-ramp. Each year, roughly four million Americans stop a GLP-1 after losing at least 15% of their body weight and fall within the BMI range we studied. That is the population that REMAIN-1 enrolled. Those patients are concentrated in ASMBS centers of excellence that we can name. There are about 1,000 accredited bariatric centers in the U.S.
Our launch plan focuses on the top 100 to 200 of them, many of them sites that we already know from our clinical program. Each of those centers already sees more than 2,000 GLP-1 patients a year, and we model 250 to 500 Revita procedures per center per year at maturity, well within each center's capacity. The metabolic interventionalist physicians in those centers already have the skills and the enthusiasm for procedures like Revita. In REMAIN-1, a half day of training and about four proctored cases brought them to proficiency. That, backed by a capital-efficient center of excellence model, is why we believe a commercial team of tens of people, not hundreds, can support a launch. In 2025, before our pivotal data, we commissioned third-party market research across roughly 750 patients, prescribers, and hospital stakeholders. Three findings stand out from that market research.
First, patients understand the risks of discontinuation very well. Nearly eight in 10 patients were both already aware of and very concerned about regaining weight after stopping a GLP-1. Over 80% ranked a one-time procedure that lets them stop their GLP-1 without regaining weight as among the features that mattered most to them. The patients most interested were those who are currently on a GLP-1. Amazingly, despite the very well-known benefits of long-term GLP-1 treatment, one in three surveyed GLP-1 users would prefer to stop taking their GLP-1 and undergo a hypothetical endoscopic procedure than continue staying on their drug. Prescribers told us the evidence that moves them most is what happens to the patients in the Revita arm, which is exactly how REMAIN-1 reads out. Second, patients want to make this decision with their doctor, and that is good news for Revita.
The metabolic interventionalists we are building our launch around already have these patients in their practices and are excited about offering them Revita if it is cleared. Third, the physicians who perform procedures are ready. Interventional practices in the research were highly interested in adopting Revita, and their concerns centered on economics and validating outcomes, which is exactly what our reimbursement work and REMAIN-1 are designed to address. That is why our launch centers on metabolic interventionalists, the bariatric surgeons, and advanced endoscopists who already manage GLP-1 patients and already perform procedures. The independent physicians who joined our commercial strategy day and our data calls over the past several months told us this conversation is part of their practice day in and day out. One question that we often hear, "Do oral GLP-1s change this picture?" We don't think so.
What patients valued most was the ability to stop either a weekly injection or a daily pill. A daily pill may change how a patient takes a GLP-1, it may increase the number who start a GLP-1, but it does not change their perspective on whether they want to stay on a GLP-1. Our view is simple. Every initiation, oral or injectable, is a potential future discontinuation risk for which an off-ramp is a needed treatment alternative. This brings me to reimbursement, where there are three components, and all three have made significant headway in the past quarter. On coding, the AMA published CPT Category III code 1122T on October 2nd, a dedicated code for the Revita procedure that will be effective January 1st, 2027.
On payment, if Revita qualifies for CMS transitional pass-through payment, which we believe it will, that could help hospitals recover the catheter costs and their contribution margin during the early launch period. On coverage, CMS has proposed RAPID, a new coverage pathway that could align Medicare coverage with FDA authorization for Breakthrough Devices. The open question for Revita is how devices like ours, with pivotal trials already underway, get to participate in RAPID. The response during the comment period was overwhelming. More than 160 comments were filed, nearly all of them supported an on-ramp, including the major medical societies and the device industry associations, MDMA and AdvaMed. Several went further and named Revita specifically. ASGE and ASMBS pointed to Revita as an example of the devices for which CMS needs to find a solution.
They were joined by a joint AGA and ASGE letter, the Obesity Action Coalition patient advocacy group, and leading bariatric and endoscopic physicians writing on their own behalf. We expect to learn whether CMS adopts an on-ramp by early January. If Revita is included, it could offer a materially better coverage position than our base case assumes. Remember, the Medicare GLP-1 Bridge Program is expanding GLP-1 access for seniors through the end of 2027. A federal program is creating and time-limiting the exact population that Revita is designed to serve. The patients are there, the physicians are there, the payment pathway is taking shape. Revita is being built to be the missing piece. Now let's talk about how we have rebuilt Fractyl around Revita. On October 21st, in consultation with our board, we decided to streamline the company's operations, workforce, and business to become hyper-focused on Revita's near-term objectives.
The goal is to get through our upcoming clinical, regulatory, and early commercialization milestones as efficiently as possible. That meant reducing our workforce by approximately 45% and discontinuing internal development of our Rejuva gene therapy program. Given the current financing environment for biotech, it is our duty to adapt to the reality of the situation, and we have. This was a painful thing to go through. These decisions affect colleagues who helped bring Revita to this point. I value each one, and I'm grateful for everything they have done to bring Fractyl to where it is today. As these changes take effect and our pivotal study spending winds down, we expect our quarterly operating cash spending to fall by approximately half to approximately $8 million by the end of the second quarter of 2027.
Our cash runway now extends into the second quarter of 2027 through our planned De Novo submission and our 12-month pivotal data. We also added to our board this month, welcoming Mike Wartell as an independent director. Michael brings extensive experience serving on public and private company boards, and we're glad to have his perspective as we execute on the milestones ahead. I also want to thank Jay Caplan, our wonderful co-founder and former president, my dear friend, who's been instrumental in helping build this company. Jay retired from his executive roles at the end of October. The result of all of this is a smaller, more efficient, more focused company with one priority, delivering on Revita's near-term milestones. Lara?
Thank you, Harith. The story of this quarter is discipline. Lower operating expenses today and a clear path to cutting our quarterly operating cash spending roughly in half. Research and development expenses were $12.5 million for the third quarter of 2026, compared with $17.5 million for the same period in 2025. The decrease of $5 million was primarily related to reduced spending on our Revita and Rejuva programs, as well as lower personnel-related expenses. SG&A expenses were $6.2 million for the quarter, compared with $5.2 million for the same period in 2025. The increase of $1 million was primarily driven by higher personnel-related and stock compensation expenses. We reported a net loss of $14.2 million for the third quarter of 2026, compared with a net loss of $45.6 million for the same period in 2025.
The $31.5 million decrease was driven by a $25.7 million favorable change in the non-cash fair value of our warrant liabilities and a $4 million reduction in operating expenses, with smaller movements in the fair value of notes payable and interest income. Adjusted EBITDA was negative $16 million for the quarter, compared with negative $20.8 million in the third quarter of 2025, a $4.8 million improvement driven by reduced operating expenses, excluding stock compensation. As of September 30, 2026, we had $31.5 million in cash and cash equivalents. I want to draw your attention to one point on our run rate. Cash used in operations was just below $16 million in the third quarter, which still reflects REMAIN-1 pivotal cohort spending and our cost structure before the reprioritization.
As cost reductions take effect and pivotal expenditures decline, we expect quarterly operating cash spending to be reduced by approximately 50% to approximately $8 million by the end of the second quarter of 2027. We expect to incur approximately $2 million in severance and related charges, the majority in the fourth quarter. Based on our current operating plan and anticipated expense reductions, we believe our cash position will be sufficient to fund operations into the second quarter of 2027 through our planned De Novo submission and the anticipated top-line one-year data from the REMAIN-1 pivotal cohort. With that, I'll turn it back to Harith.
Thank you, Lara. Let me close where I started. Revita is designed to reset the gut's metabolic memory. REMAIN-1 met its six-month co-primary endpoint with high statistical significance in the most rigorous stress test that we could conceive. The patients and physicians are there, and the payment pathway is taking shape. We have rebuilt Fractyl around Revita with the runway to get through the milestones directly in front of us. Over the next several months, there are three milestones I want you to be focused on. First is the submission of our De Novo marketing application, which we plan to begin in the late fourth quarter of 2026. Second, our 12-month pivotal data in the first quarter of 2027, including the second co-primary endpoint, key secondary endpoints, and dose response analyses.
Success there means meeting the regulatory performance goal and roughly half the regain of sham at full ablation length. Third, clarity on the CMS RAPID reimbursement rule. We expect to learn by Q1 whether CMS adopts an on-ramp for devices like Revita that have pivotal trials already underway, and we are optimistic that they will find such a path. Beyond those, we see a potential FDA marketing authorization in late 2027 and a potential U.S. commercial launch in early 2028. I want to thank the patients in REMAIN-1 who have trusted us with their health and their persistence, the investigators and operators who have executed this trial with real skill, our employees, including the colleagues leaving us this quarter, whose focus through an unusually demanding stretch has been exceptional.
I want to thank our shareholders, including the many individual investors who sent us questions for the very first time, whose conviction in the science makes all of it possible. This is the moment Fractyl was built for. We've never been more focused on delivering on what comes next. Brian, let's start with those questions.
Thanks, Harith. We'll begin with questions submitted by our shareholders through Say by Robinhood. I'll read a selection of the most voted questions, combining a few that overlap. The first question is, what concrete steps are the board and management taking to restore credibility with investors, including institutional investors?
Thank you for asking directly. Credibility is earned by doing what we say we will do, and I would point to four steps. First, the data. REMAIN-1 met its six-month co-primary endpoint in a randomized double-blinded sham-controlled study with high statistical significance. Second, discipline. With our board, we made difficult decisions last month to focus the company entirely on Revita and to put us on a path to cut quarterly operating cash spending by approximately half. Third, governance. This month, we added Mike Wartell to our board as an independent director. Fourth, we remain committed to keeping a continuous dialogue with our institutional and retail investors alike. From here, we expect to be judged on execution, De Novo submission, 12-month data, and clarity on RAPID.
Great. The next question combines a few on funding. How does the company plan to fund its upcoming milestones, and are you exploring strategic partnerships, licensing agreements, or a potential acquisition?
We ended the quarter with $31.5 million in cash and cash equivalents. Based on our current operating plan, we believe that that is sufficient to fund operations into the second quarter of 2027 through our planned De Novo submission and the 12-month REMAIN-1 data. The reprioritization we announced in October is expected to reduce quarterly operating cash spending by approximately 50% to approximately $8 million by the end of the second quarter of 2027. Based on our current operating plans, the milestones Harith described are funded with the cash we have on hand. Beyond those milestones, we will need additional capital to bring Revita to market, and we will weigh every option with shareholder value in mind. On the strategic side, we do not comment on specific discussions, and we would update you only if there was something definitive to report.
What I can say is that every milestone we deliver potentially expands our options.
Great. Thank you. The last shareholder question is about ablation length. Your data showed better results with longer ablations. What training or procedural steps are you taking so that patients in the real-world practice consistently receive a full length of treatment, or 20-plus centimeters?
This is a great question, and the answer is quite simple, actually. In our analyses, we saw a better treatment effect at longer ablation lengths. Like what we had seen in prior studies, and patients who reached 20 centimeters in a post-hoc analysis saw the greatest effect, with no associated safety signal observed. Physicians in REMAIN-1 reached that length with the current device. Each additional two centimeters takes about two minutes, and these findings inform the procedural parameters that we propose to the FDA, and if Revita is approved, will also inform our physician training program for launch.
Great. That concludes the shareholder questions. Thank you to everyone who submitted. Operator, please open the line for our analysts.
Thank you. At this time, we will conduct the question-and-answer session. As a reminder, to ask a question, you will need to press star one one on your telephone and wait for your name to be announced. To withdraw your question, please press star one one again. Please stand by while we compile our Q&A roster. Our first question will come from the line of Angela Qian of Canaccord Genuity. Your line is now open.
Hey, guys. Thank you for taking our questions. This is Angela on for Whitney. Question on the Medicare patient population. It sounds like that population could really represent a significant portion of Revita patients, given the bridge program ending at the end of 2027. Since you are targeting the top 10%-20% of high-volume accredited metabolic and bariatric centers, can you maybe share what proportion of patients at those centers are currently Medicare patients?
Sure. Thank you, Angela, for the question. I would say that, yes, we are planning an early launch predicated on Medicare patients. The question that you are asking is complicated because until about six months ago, relatively few patients were Medicare patients. In our conversations in the last several weeks alone, what we are observing is that every one of our centers with whom we are in dialogue are seeing a rapid increase in the number of Medicare patients who are specifically seeking GLP-1s through this bridge program. We heard earlier in the quarter that, from David Ricks, the CEO of Eli Lilly, that 700,000 patients had joined the GLP-1 bridge program across the U.S. That number is a fraction of what Medicare anticipates will be in the U.S. It will be roughly four million to five million people on the GLP-1 bridge by around this time next year.
If you assume that there is roughly 30 million people on GLP-1s today, and let us say that is a relatively steady state number, it is going to grow by about four million to five million of GLP-1 patients who are from the bridge program alone. That is our expectation.
Got it. Thank you. If I could add, just follow up quickly with another question that piggybacks off of one of the shareholder questions that was asked. Since you had seen greater lengths of ablation result in greater efficacy, I guess, do you expect physicians to potentially require longer training than what was previously estimated since they might have to ablate a longer length? Thank you.
Well, before beginning REMAIN-1, we believed that the length of duodenal ablation could be an important determinant of treatment effect. As you saw from our Midpoint Cohort and our six-month data, we have observed an encouraging relationship between ablation length and efficacy. In our exploratory analyses, patients receiving longer ablation lengths did experience greater reduction in weight regain. The practical implication is that if longer treatment lengths are truly associated with greater benefit, and we will see that 12-month data soon, we believe that physicians can and will be trained to deliver those treatments consistently. Remember, each additional two centimeters of ablation adds approximately two minutes to the procedure. We are not talking about an entirely different intervention or a fundamentally different skill set. We are talking about optimizing the extent of treatment within a standardized endoscopic procedure with our existing tools and skills.
We have seen physicians improve their ability to deliver longer treatments as they gain experience. When you are treating more tissue or delivering a higher dose, the therapeutic window and safety matters. I just want to reiterate, importantly, we have not observed a safety signal suggesting that longer ablation lengths are associated with any additional risk of serious adverse events in the data that we have evaluated to date.
Thank you. One moment for our next question. Our next question will come from the line of Mike DiFiore of Evercore. Your line is open, Mike.
Hey, guys. Thanks so much for taking my questions. Two for me. One is regarding the potential Class II classification of Revita. Obviously, the final pathway decision follows a review of the complete safety dataset, but regarding the two events in one Revita patient that were deemed possibly related to the device or procedure, which included GI hemorrhage and acute blood loss anemia, how do you expect the FDA to treat these possibly related events when it determines the class?
I cannot speak for the FDA, but I can speak to this adverse event that you are mentioning. Just for those who may be new to the story, there was one patient who experienced possibly device or procedure-related serious adverse events, as deemed by an independent DSMB during the course of the study. This is an individual who was on two different non-steroidal anti-inflammatory drugs at the same time, which is contraindicated, for a different indication totally unrelated to Revita or the disease that we are targeting here. We know that NSAIDs carry a risk of GI bleed. This patient also had two endoscopies performed during the active bleeding episode, and no bleeding source was identified in the duodenum despite an active effort to try to find one, and no intervention was ultimately performed.
It is only because the person was in the study that we believe that this was classified as possibly. We believe that the study team did everything they could to determine whether there was a cause from the ablation, and none was found. We do not think this is going to change anyone's perception of Revita's safety profile.
Very helpful, Harith. Just one quick follow-up. What indication statement are you proposing? Is it tied to prior weight loss of at least 15% and a certain BMI window, or does it cover discontinuation of any GLP-1? Thank you.
We have not yet finalized that, so I do not want to jump ahead. I think it is reasonable to say that 15% was selected in our trial because we believe that that would be a large enough weight loss to be able to discern a treatment effect. We think that translates to Revita providing potential benefit in people who have achieved clinically meaningful weight loss on any GLP-1. Again, we used tirzepatide in the trial mainly for study homogeneity purposes. We believe that that will not be a limitation on the label itself.
Got it. Thank you.
One moment for our next question. Our next question comes from the line of Jason Gerberry of Bank of America Securities. Your line is now open.
Hey, guys. This is Chi on for Jason. Thanks for taking our questions. My first one is, what are the remaining steps or gating factors, if any, for the U.S. filing in late 2026? Have you met with the FDA after the pivotal readout, the six-month readout, or would you need to meet with the FDA before the filing? If that's the case, what are sort of discussions or feedback are you aiming to get at the meeting?
We have not met with the FDA. We got a lot of feedback during the course of the year in interactive discussions because we are a Breakthrough Device. We do not anticipate any specific FDA feedback required beginning before our submission. We are working on compiling the elements of our submission right now. I think that the gating item will clearly be, I would say, that you can reasonably expect that when the second co-primary endpoint for REMAIN-1 will read out in the first quarter of 2027, those data will also be an important part of completing the clinical evidence package supporting our application. So, while we've been preparing the design, the manufacturing, the other technical components of our De Novo application for quite some time, our plan is to advance those components in the fourth quarter of this year.
We are targeting the completion with the full clinical package in the first quarter of 2027.
Got it. My follow-up question is sort of maybe perhaps thinking about further down the line.
As we step back, a couple of the observations you have made up from the data is that longer ablation length lead to better efficacy, and also potentially bigger the weight loss prior to GLP-1 discontinuation, the better the efficacy. As you think about further down the line, as there are potentially more novel GLP-1 therapies, maybe more potent therapies, what are the opportunities to sort of doing post-marketing studies to sort of revisit Revita potential as the treatment landscape evolves?
Well, we actually think one of the interesting and underappreciated elements of this story is that as the drug manufacturers get better at developing more potent agents that deliver more weight loss more rapidly, the need for a off-ramp actually only grows. Let's take some of the more recent drugs that are delivering even more profound weight loss than those that are already approved. We have clearly heard from clinical trial sites that when these studies end, after patients have lost 40%, 45% of their body weight, then they no longer have access to the medicines, they are so hungry, they are eating everything in their pantry. We've heard from one clinical investigator that they have had patients who've eaten their dog food and their cat food when they ran out of food in the pantry.
Because when you lose that much weight and then the medicine is taken away from you, the body's physiologic drive to eat and regain weight is so profound, I believe the need for a manner to be able to blunt that regain is going to be even more important as the drugs get better.
Okay, great. Thank you for taking our questions.
One moment for our next question. Our next question comes from the line of Chase Knickerbocker of Craig-Hallum. Your line is now open.
Good afternoon, guys. Thanks for taking the questions. Just one from me. Following the restructuring and the actions you've taken to extend runway, just trying to get a sense for how you're thinking about the initial go-to-market and how that thinking may have changed. Question being, how lean do you think you can be initially and still effectively target those first 50 to 100 potential centers of excellence? Whether you just want to discuss any update to how you're seeing commercial infrastructure build, or if you would be willing to discuss what you think it'll cost in that first year. That'd be great. Thanks.
Yeah. Thanks, Chase. We made substantial reductions to our workforce, it is true, but it's also important to understand that we've also fundamentally focused our company on the highest value activities as our needs have evolved. Number one, with the discontinuing our Rejuva program. Number two, as our clinical trial is coming to a close, the amount of money and effort spent on that is reducing. Number three, as we have been finalizing our design and manufacturing modules, a lot of the work required in order to be able to prepare that device to be able to launch has been completed. While we've made those changes, and those changes have allowed us to reduce our spending and concentrating our resources, that's what's allowed our operating cash spending to decline in the manner that it has.
But we're not trying to execute the same operating plan with half the resources. We're just executing a much more focused plan. When we think about commercialization, remember, we're not planning a broad, highly resource-intensive launch from day one. As we outlined in our September investor day, our strategy is to begin with a very targeted group of established bariatric and metabolic centers of excellence. They already have the patients, physicians, and procedural infrastructure that Revita would need, and that does give us the ongoing opportunity, subject to authorization and reimbursement and financing, to continue to be able to demonstrate early commercial adoption as we have already laid out. So, we remain committed to being able to move towards the plan that we have laid out for you before.
Understood. Thanks.
Thank you. One moment for our next question. Our next question will be coming from the line of Jeffrey Cohen of Ladenburg Thalmann & Company Inc. Your line is now open.
Good afternoon. Thanks for taking our questions. Just one from our end, I guess. Lara, as you talked about the one-time severance for Q4, could you give us a sense of SG&A versus R&D, and then give us also a sense of how the spend on SG&A and R&D plays out over the next few quarters?
Look, we haven't given any guidance actually on the split between SG&A and R&D. I would just say that we have reduced, as Harith said, we focused throughout the entire company and reprioritized, and the $2 million, it will be spread roughly in the same proportions that you could expect it to be with SG&A and R&D that we have today. We'll give more information as we can. What we can say is that we have reduced our burn and expect it to come down to approximately 50% or $8 million by the end of Q2 2027.
Okay, perfect. Thanks for taking our question.
Thank you. I'll now turn the call back to Dr. Harith Rajagopalan for closing remarks.
Thank you, everyone. Thank you to the shareholders who sent in questions for the first time. Three things to watch from here: planned De Novo submission, clarity on the CMS RAPID rule, top-line 12-month data from the REMAIN-1 pivotal cohort in the first quarter of 2027. We are funded through each of them. We look forward to updating you as we deliver. Thank you all.
This concludes today's conference call. Thank you for participating. You may now disconnect.
Related articleQuarter not tagged2026-11-06Fractyl Health to Report Third Quarter 2026 Financial Results and Provide Business Updates on November 12, 2026
GlobeNewswire
Fractyl Health to Report Third Quarter 2026 Financial Results and Provide Business Updates on November 12, 2026
BURLINGTON, Mass., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the Company or Fractyl), a clinical-stage metabolic therapeutics company focused on pioneering novel approaches to treat obesity and type 2 diabetes (T2D), today announced that it will report financial results for the third quarter 2026 and provide business updates on Thursday, November 12, 2026, at 4:30 p.m. ET. A live webcast of the conference call and presentation can be accessed in the "Events" section of Fractyl Health's website at http://ir.fractyl.com. The webcast will be archived and available for replay following the live event. To enhance engagement with the company's shareholder base, Fractyl Health is partnering with Say Technologies to allow retail and institutional shareholders to submit and upvote questions, a selection of which will be answered during the earnings call. Shareholders can submit questions by visiting: https://app.saytechnologies.com/fractyl-health-2026-q3. This Q&A platform will remain open until 4:30 p.m. ET on November 11, 2026. Shareholders can email [email protected] for any support inquiries. About Fractyl Health Fractyl is a clinical-stage metabolic therapeutics company focused on pioneering novel approaches to treat obesity and type 2 diabetes. The Company's lead product candidate, Revita, is an endoscopic procedural therapy in pivotal development for post-GLP-1 weight maintenance. Fractyl's goal is to change the course of metabolic disease, advancing treatment from chronic management toward prevention and reversal of disease. Fractyl is headquartered in Burlington, Massachusetts. Contact Brian Luque, Head of Investor Relations and Corporate Development [email protected], 951.206.1200
Related articleQuarter not tagged2026-10-22Fractyl Health Sharpens Focus on Revita Following Positive Pivotal Results, Advancing Toward Planned FDA De Novo Submission in Post-GLP-1 Weight Maintenance
GlobeNewswire
Fractyl Health Sharpens Focus on Revita Following Positive Pivotal Results, Advancing Toward Planned FDA De Novo Submission in Post-GLP-1 Weight Maintenance
Following positive topline six-month REMAIN-1 pivotal results, Revita advancing toward planned FDA De Novo submission in late Q4 2026 and anticipated 12-month pivotal data readout in Q1 2027 Workforce reduction aligns organization behind Revita's near-term clinical and commercial opportunity Company discontinuing development of Rejuva candidates and seeking strategic alternatives to maximize the value of its Rejuva gene therapy program Cash runway extended into Q2 2027; quarterly operating cash burn expected to be reduced by ~50% to approximately $8 million by end of Q2 2027 BURLINGTON, Mass., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the Company or Fractyl), a clinical-stage metabolic therapeutics company focused on pioneering novel approaches to treat obesity and type 2 diabetes (T2D), today announced that it is sharpening its focus and concentrating its financial and operational resources on advancing Revita®, its lead product candidate, toward potential U.S. Food and Drug Administration (FDA) marketing authorization and commercialization in post-GLP-1 weight maintenance. The decision follows the Company's recent announcement of positive topline six-month results from the REMAIN-1 Pivotal Cohort, which met its prespecified six-month co-primary endpoint with high statistical significance in weight regain compared to sham (p=0.0023). The Company believes these results reinforce Revita's potential to become the first durable procedural therapy for post-GLP-1 weight maintenance, addressing what the Company believes is one of the largest unmet needs in obesity care as millions of patients seek sustainable solutions to maintain weight loss following GLP-1 discontinuation. To support this sharpened focus, Fractyl will implement a reduction in force affecting approximately 45% of its workforce. These actions are intended to create a streamlined, Revita-focused organization, reduce quarterly cash burn by approximately 50% by the end of Q2 2027 and concentrate resources on realizing Revita's clinical and commercial potential. Fractyl will also discontinue internal development of its Rejuva gene therapy program and is seeking strategic alternatives to maximize the value of the program. In conjunction with these organizational changes, Jay Caplan, Co-Founder, President and Chief Product Officer of Fractyl, will retire from his executive r…Read full documentShow less
Following positive topline six-month REMAIN-1 pivotal results, Revita advancing toward planned FDA De Novo submission in late Q4 2026 and anticipated 12-month pivotal data readout in Q1 2027 Workforce reduction aligns organization behind Revita's near-term clinical and commercial opportunity Company discontinuing development of Rejuva candidates and seeking strategic alternatives to maximize the value of its Rejuva gene therapy program Cash runway extended into Q2 2027; quarterly operating cash burn expected to be reduced by ~50% to approximately $8 million by end of Q2 2027 BURLINGTON, Mass., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the Company or Fractyl), a clinical-stage metabolic therapeutics company focused on pioneering novel approaches to treat obesity and type 2 diabetes (T2D), today announced that it is sharpening its focus and concentrating its financial and operational resources on advancing Revita®, its lead product candidate, toward potential U.S. Food and Drug Administration (FDA) marketing authorization and commercialization in post-GLP-1 weight maintenance. The decision follows the Company's recent announcement of positive topline six-month results from the REMAIN-1 Pivotal Cohort, which met its prespecified six-month co-primary endpoint with high statistical significance in weight regain compared to sham (p=0.0023). The Company believes these results reinforce Revita's potential to become the first durable procedural therapy for post-GLP-1 weight maintenance, addressing what the Company believes is one of the largest unmet needs in obesity care as millions of patients seek sustainable solutions to maintain weight loss following GLP-1 discontinuation. To support this sharpened focus, Fractyl will implement a reduction in force affecting approximately 45% of its workforce. These actions are intended to create a streamlined, Revita-focused organization, reduce quarterly cash burn by approximately 50% by the end of Q2 2027 and concentrate resources on realizing Revita's clinical and commercial potential. Fractyl will also discontinue internal development of its Rejuva gene therapy program and is seeking strategic alternatives to maximize the value of the program. In conjunction with these organizational changes, Jay Caplan, Co-Founder, President and Chief Product Officer of Fractyl, will retire from his executive roles with the Company, effective October 30, 2026. Mr. Caplan is expected to continue to support the Company as a senior advisor to the leadership team. "We believe the positive pivotal results from REMAIN-1 represent a defining moment for Fractyl and represent an enormous opportunity for Revita potential to fundamentally change how obesity is treated and offer a durable approach to weight maintenance," said Harith Rajagopalan, M.D., Ph.D., Co-Founder and Chief Executive Officer of Fractyl. "A million patients per month in the United States face the challenge of weight regain after discontinuing GLP-1 therapies. Our goal is for Revita to establish an entirely new therapeutic category by aiming to reverse years of diet-induced damage to the gut. We expect the capital we have today to be sufficient to fund our planned De Novo submission and upcoming 12-month pivotal data, and we are excited to focus our attention and align our resources behind our near-term opportunity. "While these decisions are difficult, particularly those impacting our colleagues, we believe this focused strategy will position Fractyl to operate more efficiently and advance Revita toward its clinical and commercial potential. I also want to personally thank my fellow co-founder, Jay Caplan, for his leadership, partnership and invaluable contributions to Fractyl over the years. Jay has been instrumental in building the Company. We are deeply grateful for his dedication and lasting contributions, as well as those of all our colleagues affected by this transition." Strategic Actions to Advance Revita, Reduce Cash Burn and Extend Runway The Company is implementing the following measures to support execution through upcoming potential clinical and regulatory milestones. - Workforce Reduction: The Company will reduce its workforce by approximately 45%, with the reduction expected to be substantially completed by November 2026. - Extended Cash Runway: Based on its current operating plan and anticipated expense reductions, including the expected cash costs associated with the reprioritization, the Company expects its existing cash and cash equivalents to fund operations into Q2 2027. - Reduced Quarterly Cash Burn: As cost reductions take effect and REMAIN-1 Pivotal Cohort expenditures decline, the Company expects operating quarterly cash burn to be reduced by approximately 50%, to approximately $8 million, by end of Q2 2027. - Rejuva Strategic Alternatives: The Company will discontinue internal development of its Rejuva gene therapy program and seek strategic alternatives to maximize the value of the program. There can be no assurance that the Company's review of strategic alternatives for Rejuva will result in any transaction, and the Company does not intend to disclose further developments unless and until it determines that disclosure is appropriate or required. Fractyl Forward: Advancing Revita Toward a New Therapeutic Category in Obesity Care The Company continues to anticipate the following anticipated milestones: - Late Q4 2026: Planned FDA De Novo marketing application submission for Revita in post-GLP-1 weight maintenance. - Q1 2027: Anticipated topline 12-month data from the REMAIN-1 Pivotal Cohort, including the second co-primary endpoint. - Late 2027: Potential FDA marketing authorization. - Early 2028: Potential U.S. commercial launch. About Revita The Revita® DMR System is Fractyl's lead product candidate, designed to remodel the duodenal lining via a single, minimally invasive endoscopic procedure intended to restore healthy nutrient sensing and signaling disrupted by chronic metabolic disease. By targeting duodenal dysfunction, Revita is designed to address an underlying driver of obesity and enable durable weight maintenance following GLP-1 discontinuation. Revita has received FDA Breakthrough Device Designation for weight maintenance in people with obesity who discontinue GLP-1 therapies. Revita is for investigational use only in the United States and is CE marked in the European Union and United Kingdom. About Fractyl Health Fractyl is a clinical-stage metabolic therapeutics company focused on pioneering novel approaches to treat obesity and type 2 diabetes. The Company's lead product candidate, Revita, is an endoscopic procedural therapy in pivotal development for post-GLP-1 weight maintenance. Fractyl's goal is to change the course of metabolic disease, advancing treatment from chronic management toward prevention and reversal of disease. Fractyl is headquartered in Burlington, Massachusetts. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact are forward-looking statements. These statements may be identified by words such as "aims," "anticipates," "believes," "could," "estimates," "expects," "forecasts," "goal," "intends," "may," "plans," "possible," "potential," "seeks," "will" and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, without limitation, statements regarding: the potential benefits of the Company's sharpened strategic focus and reprioritization, including the proposed workforce reduction and its anticipated impact on the Company's expenditures and financial runway; the promise and potential impact of the Company's clinical trial data and product candidates, including Revita's potential for maintaining weight loss after GLP-1 based therapy discontinuation and its potential to be the first procedural therapy for post-GLP-1 weight maintenance; the design, initiation, timing and results of clinical studies or readouts, including readouts from the REMAIN-1 Pivotal Cohort, including 12-month data; the potential launch or commercialization of any of the Company's product candidates or products; the Company's regulatory strategy, including the timing of any potential De Novo marketing application submission and the potential use and benefits of the De Novo pathway (FDA pre-submission feedback is advisory and non-binding, or as to the timing of any such authorization); the potential treatment population or benefits for any of the Company's product candidates or products; the Company's strategic and product development objectives and goals; the Company's expected quarterly cash burn and cash runway; the Company's exploration of strategic alternatives for Rejuva and the potential benefits thereof; and the timing of any of the foregoing. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the risks that are discussed more fully in its filings with the Securities and Exchange Commission (the SEC), including the "Risk Factors" section of its Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 24, 2026, and other documents it subsequently files with or furnishes to the SEC, including its Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, filed with the SEC on August 10, 2026. These forward-looking statements are based on management's current estimates and expectations. While the Company may elect to update such forward-looking statements at some point in the future, it disclaims any obligation to do so, even if subsequent events cause its views to change. Contact Brian Luque, Head of Investor Relations and Corporate Development [email protected], 951.206.1200
Related articleQuarter not tagged2026-08-12Fractyl Health, Inc. Common Stock Q2 2026 Earnings Call Summary
Moby
Fractyl Health, Inc. Common Stock Q2 2026 Earnings Call Summary
Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here. Management identifies a massive market opportunity in the approximately 1 million patients discontinuing GLP-1 therapies monthly, who currently face rapid weight regain without a durable alternative. Revita's clinical thesis is supported by 1-year randomized data showing patients maintained over 80% of prior weight loss compared to 46% in the sham arm, suggesting a potential plateau in weight maintenance rather than just delayed regain. The pivotal REMAIN-1 study is strategically enriched for complete ablation length and higher run-in weight loss, the two variables management identified as primary drivers of treatment effect size. The safety profile is highlighted as a key adoption driver, with zero device-related serious adverse events and only mild, transient treatment-emergent adverse events reported in the midpoint cohort. Management views the rise of oral GLP-1s as a demand engine rather than a threat, as easier initiation likely leads to higher absolute volumes of future discontinuations requiring an off-ramp. Strategic positioning focuses on leveraging existing GI clinical workflows and endoscopy suites, requiring no new site of care for rapid commercial integration. The company has maintained fiscal discipline, reducing cash outlay post-randomization to ensure the current $47.1 million runway extends through the pivotal data readout and potential FDA submission. Anticipate reporting top-line 6-month primary endpoint data from the REMAIN-1 pivotal cohort in early Q4 2026, followed by 12-month data in Q1 2027. Plan to submit a potential FDA de novo marketing application in late Q4 2026, supported by feedback that Revita's safety profile is consistent with a moderate-risk classification. Guidance assumes both co-primary endpoints in the pivotal trial are powered above 95% based on midpoint cohort performance and enrichment strategies. Expect to dose the first patient in the Rejuva-001 gene therapy study imminently, with preliminary safety and feasibility data anticipated in the second half of 2026. Commercial strategy assumes a targeted launch into 100 to 200 high-throughput U.S. centers of excellence where bariatric and metabolic endoscopy expertise already exists. The Medicare GLP-1 Bridge demonstrati…Read full documentShow less
Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here. Management identifies a massive market opportunity in the approximately 1 million patients discontinuing GLP-1 therapies monthly, who currently face rapid weight regain without a durable alternative. Revita's clinical thesis is supported by 1-year randomized data showing patients maintained over 80% of prior weight loss compared to 46% in the sham arm, suggesting a potential plateau in weight maintenance rather than just delayed regain. The pivotal REMAIN-1 study is strategically enriched for complete ablation length and higher run-in weight loss, the two variables management identified as primary drivers of treatment effect size. The safety profile is highlighted as a key adoption driver, with zero device-related serious adverse events and only mild, transient treatment-emergent adverse events reported in the midpoint cohort. Management views the rise of oral GLP-1s as a demand engine rather than a threat, as easier initiation likely leads to higher absolute volumes of future discontinuations requiring an off-ramp. Strategic positioning focuses on leveraging existing GI clinical workflows and endoscopy suites, requiring no new site of care for rapid commercial integration. The company has maintained fiscal discipline, reducing cash outlay post-randomization to ensure the current $47.1 million runway extends through the pivotal data readout and potential FDA submission. Anticipate reporting top-line 6-month primary endpoint data from the REMAIN-1 pivotal cohort in early Q4 2026, followed by 12-month data in Q1 2027. Plan to submit a potential FDA de novo marketing application in late Q4 2026, supported by feedback that Revita's safety profile is consistent with a moderate-risk classification. Guidance assumes both co-primary endpoints in the pivotal trial are powered above 95% based on midpoint cohort performance and enrichment strategies. Expect to dose the first patient in the Rejuva-001 gene therapy study imminently, with preliminary safety and feasibility data anticipated in the second half of 2026. Commercial strategy assumes a targeted launch into 100 to 200 high-throughput U.S. centers of excellence where bariatric and metabolic endoscopy expertise already exists. The Medicare GLP-1 Bridge demonstration, launched July 1, 2024, is viewed as a critical catalyst for payer convergence on the need for durable, non-pharmacological solutions. Final regulatory pathway determination (de novo vs. PMA) remains subject to the FDA's review of the complete safety data set included in the future submission. Management explicitly stated they do not plan to raise capital before pivotal data is in hand, Management stated that the company is funded through definitive data and that there is no planned capital raise before the pivotal data readout. Rejuva-001 clinical development is funded within the existing runway and is not expected to compete with Revita for capital resources. Management declined to provide specific volume numbers ahead of the September Investor Day but emphasized that the health economic value proposition is higher than previously realized. Physician training is expected to be rapid, as the procedure leverages existing endoscopic skills and typically requires fewer than five procedures for proficiency. One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here. Payers are expected to focus on the pivotal trial's specific patient profile, including the 15% run-in weight loss threshold and prior GLP-1 use. Medicare has expressed specific concerns regarding muscle mass loss and frailty in elderly populations on GLP-1s, which may favor a procedural maintenance option. Revita is expected to qualify for transitional pass-through payment from day one of launch due to its Breakthrough Device status and novelty within the CPT schema. CMS recently reaffirmed rules that ensure these payment mechanisms remain in place for the next several years. Management claims a broad patent estate covering both thermal and non-thermal ablation for metabolic conditions, including post-GLP-1 weight maintenance. The company intends to defend its market position as the first-mover in duodenal ablation innovation. The study utilizes staggered sentinel dosing, requiring a 14-day safety monitoring period for the first patient before others in the cohort can be dosed. Initial data will focus strictly on safety, feasibility of device delivery, and tolerability rather than long-term efficacy.
Related articleQuarter not tagged2026-08-11Fractyl Health Inc (GUTS) (Q2 2026) Earnings Call Highlights: Pivotal Data on Track and ...
GuruFocus.com
Fractyl Health Inc (GUTS) (Q2 2026) Earnings Call Highlights: Pivotal Data on Track and ...
This article first appeared on GuruFocus. Cash Position: $47.1 million in cash and cash equivalents as of June 30, 2026. R&D Expenses: $13.8 million for Q2 2026, down from $21.2 million in Q2 2025. SG&A Expenses: $5.3 million for Q2 2026, up from $4.9 million in Q2 2025. Net Loss: $25.5 million for Q2 2026, compared with a net loss of $27.9 million in Q2 2025. Adjusted EBITDA: Negative $16.3 million for Q2 2026, improved from negative $24 million in Q2 2025. Cash Used in Operations: Approximately $16 million in Q2 2026. Warning! GuruFocus has detected 2 Warning Signs with GUTS. Is GUTS fairly valued? Test your thesis with our free DCF calculator. Release Date: August 10, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Fractyl Health Inc (NASDAQ:GUTS) reported positive one-year randomized data from the REMAIN-1 midpoint cohort, showing Revita patients maintained over 80% of GLP-1-induced weight loss versus 46% for sham, with no patients reinitiating GLP-1 therapy. The company highlighted an unusually clean safety profile for Revita, with zero device or procedure-related serious adverse events through one year and only four mild, transient adverse events in the entire midpoint cohort. The REMAIN-1 pivotal cohort is well-powered above 95% on both co-primary endpoints and enriched for variables associated with greater treatment effect, including a median ablation length of 16 cm and mean run-in weight loss of 18.3%. Fractyl Health Inc (NASDAQ:GUTS) has a clear regulatory path with FDA feedback indicating Revita's safety profile is consistent with a moderate-risk device classification, and it remains on track for a potential de novo submission in late Q4 2026. The company is funded through early 2027, extending beyond the pivotal data readout and potential de novo submission, with no plans to raise capital before pivotal data is in hand. Fractyl Health Inc (NASDAQ:GUTS) received clinical trial authorization in the Netherlands and ethics committee approval in Australia for RJVA-001, the first AAV-based gene therapy candidate for type 2 diabetes, with initial data expected in the second half of 2026. Fractyl Health Inc (NASDAQ:GUTS) reported a net loss of $25.5 million for Q2 2026, though this was an improvement from the $27.9 million loss in the same period of 2025. The company's cash position stands at $47…Read full documentShow less
This article first appeared on GuruFocus. Cash Position: $47.1 million in cash and cash equivalents as of June 30, 2026. R&D Expenses: $13.8 million for Q2 2026, down from $21.2 million in Q2 2025. SG&A Expenses: $5.3 million for Q2 2026, up from $4.9 million in Q2 2025. Net Loss: $25.5 million for Q2 2026, compared with a net loss of $27.9 million in Q2 2025. Adjusted EBITDA: Negative $16.3 million for Q2 2026, improved from negative $24 million in Q2 2025. Cash Used in Operations: Approximately $16 million in Q2 2026. Warning! GuruFocus has detected 2 Warning Signs with GUTS. Is GUTS fairly valued? Test your thesis with our free DCF calculator. Release Date: August 10, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Fractyl Health Inc (NASDAQ:GUTS) reported positive one-year randomized data from the REMAIN-1 midpoint cohort, showing Revita patients maintained over 80% of GLP-1-induced weight loss versus 46% for sham, with no patients reinitiating GLP-1 therapy. The company highlighted an unusually clean safety profile for Revita, with zero device or procedure-related serious adverse events through one year and only four mild, transient adverse events in the entire midpoint cohort. The REMAIN-1 pivotal cohort is well-powered above 95% on both co-primary endpoints and enriched for variables associated with greater treatment effect, including a median ablation length of 16 cm and mean run-in weight loss of 18.3%. Fractyl Health Inc (NASDAQ:GUTS) has a clear regulatory path with FDA feedback indicating Revita's safety profile is consistent with a moderate-risk device classification, and it remains on track for a potential de novo submission in late Q4 2026. The company is funded through early 2027, extending beyond the pivotal data readout and potential de novo submission, with no plans to raise capital before pivotal data is in hand. Fractyl Health Inc (NASDAQ:GUTS) received clinical trial authorization in the Netherlands and ethics committee approval in Australia for RJVA-001, the first AAV-based gene therapy candidate for type 2 diabetes, with initial data expected in the second half of 2026. Fractyl Health Inc (NASDAQ:GUTS) reported a net loss of $25.5 million for Q2 2026, though this was an improvement from the $27.9 million loss in the same period of 2025. The company's cash position stands at $47.1 million, which provides runway only into early 2027, creating potential financing needs if pivotal data or regulatory milestones are delayed. The ATM facility remains closed, and management has stated it does not plan to raise capital before pivotal data, which could limit financial flexibility if unexpected costs arise. The pivotal study's success depends on maintaining high retention rates and low medication resumption, which are operational risks that could impact the final data readout. The company faces uncertainty regarding payer reimbursement criteria for Revita, as payers may impose strict requirements around prior GLP-1 use, weight loss thresholds, and documented discontinuation before covering the procedure. The Rejuva gene therapy program is in early stages, with the first patient dosing pending site activation, and the company has not provided a timeline for FDA discussions, indicating potential delays in this pipeline asset. Q: What is the expectation for reimbursement upon approval, particularly regarding transitional coverage for emerging technologies given the breakthrough device designation, and what are the risks related to the filing timeline or De Novo versus PMA pathway? Additionally, what size of commercial infrastructure will be needed to support Revita?A: Harith Rajagopalan, CEO, explained that CMS's transitional pass-through payment mechanism has a clear statutory requirement, and breakthrough devices that achieve clearance or approval automatically qualify if they are novel and don't fit into an existing CPT schema. He noted that CMS recently reaffirmed this rule, providing confidence that Revita can have reimbursement from day one at launch. Regarding commercial infrastructure, he outlined a targeted and efficient center of excellence model focused on the top 100-200 endoscopy health systems, which perform at least half of endoscopies in the US. The company plans to leverage existing strong relationships with endoscopists focused on bariatric and metabolic endoscopy, enabling a smaller, highly focused team targeting high-throughput centers. Q: Can you confirm whether the final Statistical Analysis Plan (SAP) was submitted and if there was any response or correspondence with the FDA regarding recent tweaks? Also, can you speak to the extent of the patent estate as it relates to other ablation technologies, particularly for weight maintenance, given the potential de novo approval rather than a PMA?A: Harith Rajagopalan, CEO, confirmed the final SAP was submitted and the company is "locked and loaded" heading into database lock. He noted there was a response from the FDA, but it was down in the schema of details rather than high-level, with nothing of materiality to discuss. Regarding patents, he stated the company has a very broad and comprehensive patent estate as the leader in duodenal ablation innovation. The issued US patents cover not only their specific methods and devices but also broadly cover both thermal and non-thermal ablation modalities for post-GLP-1 weight maintenance, type 2 diabetes, and related conditions, and the company intends to defend that market. Q: Regarding profitability, what procedure volume per center is embedded in the assumption that Fractyl can be profitable with a targeted launch into the top 100-200 US centers, and how quickly do you expect trained physicians to ramp to that level?A: Harith Rajagopalan, CEO, declined to provide specific numbers, deferring to the upcoming Investor Day in September. However, he noted that the health economic value from Revita, based on 50 patients with one year of follow-up from REVEAL-1 and REMAIN-1, is greater than previously realized, which increases confidence in potential profitability. On training, he stated that based on observations across multiple studies, it takes less than five procedures for a physician to feel comfortable performing the procedure. The company expects to continue its successful preceptorship program, leveraging the fact that the procedure builds on existing physician skills and is not anatomy-altering, with a compelling safety profile. Q: What criteria do you expect payers or Medicare to impose around prior GLP-1 use, degree of prior weight loss, BMI, or documented discontinuation before reimbursing for Revita?A: Harith Rajagopalan, CEO, expects payers to look carefully at the patient population studied and pre-specified in the pivotal trial, likely focusing on at least 15% run-in weight loss and use of a GLP-1-based therapy. He noted that in recent conversations with payers, Medicare is particularly concerned about muscle mass loss and frailty associated with GLP-1s in the elderly population. With the Medicare bridge program expecting millions of patients to start GLP-1s and the program having a shelf life of about 18 months, payers are thinking hard about the implications of many patients needing to discontinue next year. Q: Are patients staying on GLP-1 therapy longer, or is the discontinuation rate about the same at one year, given physicians now have more experience with these medications?A: Harith Rajagopalan, CEO, stated that meta-analyses suggest the median duration of time on therapy remains in the six to nine-month range, with no significant change observed. He noted that data quality is somewhat impaired due to more people getting drugs from online pharmacies. Preliminary observations on oral GLP-1s suggest patients are staying on lower doses or not titrating as much as expected. He emphasized that the million discontinuers per month remains a "jaw-dropping" number, as these patients who have achieved clinically meaningful weight loss now face rapid weight regain, representing a huge opportunity for Revita. Q: Can you comment on the HbA1c secondary endpoint and what you anticipate the early Q4 readout of Revita will show? Do you expect it to be comparable with previous cohorts?A: Harith Rajagopalan, CEO, explained that the REMAIN pivotal study includes secondary analyses on cardiometabolic parameters including lipids and HbA1c. However, very few patients in the study were diagnosed with prediabetes at randomization, with HbA1c levels in the low fives. He expects the signal to show glycemic stability through six months rather than dramatic improvements, which alone is valuable because these patients are at high risk of developing prediabetes. The clinical signal for glycemic effects will likely take more time to mature than the six-month readout will provide. Q: What are the key outstanding points regarding going down the de novo status for Revita, and what are the key points to get to IND status in discussions with the FDA for Rejuva?A: Harith Rajagopalan, CEO, stated that the key point for Revita's de novo pathway is the FDA's review of safety data from the pivotal study, which will be included in the submission. Given the blinded safety data with regular DSMB reviews, the company is encouraged by the safety profile. For Rejuva, the plan is to generate safety, feasibility, and preliminary efficacy data from the OUS first-in-human study before approaching the FDA, though no timeline has been established for that discussion. Q: What preliminary data should we expect from the Rejuva program later this year, and can you provide early thoughts on Revita pricing?A: Harith Rajagopalan, CEO, indicated that the most important initial communication for Rejuva will be the safety and tolerability of RJVA-001 through the first 14-day sentinel period, along with the safety and feasibility of the device delivery, as this unlocks the rest of the dosing in the cohort. On Revita pricing, he deferred to the upcoming Investor Day where the company will present its view on the health economic value proposition, noting For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Related articleQuarter not tagged2026-08-10Fractyl Health Q2 Earnings Call Highlights
MarketBeat
Fractyl Health Q2 Earnings Call Highlights
Interested in Fractyl Health, Inc.? Here are five stocks we like better. Revita showed durable weight-loss maintenance: Patients retained more than 80% of prior GLP-1-related weight loss one year after stopping therapy, versus 46% for sham treatment. The company also reported roughly 78% maintenance in its open-label cohort. Pivotal data and regulatory milestones are approaching: Fractyl completed enrollment in the REMAIN-1 trial, expects six-month top-line results in early Q4 2026, and is targeting a potential FDA De Novo submission later in Q4. Financially, Fractyl reported improved losses and runway: Second-quarter net loss narrowed to $25.5 million, while $47.1 million in cash is expected to fund operations into early 2027. The company does not plan to raise capital before pivotal trial results. Fractyl Health (NASDAQ:GUTS) said its Revita endoscopic procedure showed durable weight-maintenance results one year after patients discontinued GLP-1 therapy, while the company reaffirmed plans to report pivotal trial data in early fourth-quarter 2026 and pursue a potential FDA De Novo submission later in the year. Chief Executive Officer Dr. Harith Rajagopalan said the company’s strategy is centered on offering patients a one-time procedural option to help maintain weight loss after stopping GLP-1 medicines. He cited the company’s July 15 release of one-year randomized data from the midpoint cohort of the REMAIN-1 study. → MarketBeat Week in Review – 08/03 - 08/07 According to Rajagopalan, patients treated with Revita maintained more than 80% of weight loss previously achieved with GLP-1 therapy one year after discontinuation, compared with 46% in the sham group. He said the treatment effect persisted from month six through month 12 while blinding was maintained, and no participant in that cohort restarted GLP-1 therapy. Fractyl also pointed to findings from its open-label REVEAL-1 cohort, where participants maintained about 78% of prior weight loss through one year after a single Revita procedure. Rajagopalan said the results address the question of whether Revita produces sustained separation from sham treatment or merely delays weight regain. → Quantum Earnings Week: Winners and Losers Are Finally Emerging The company completed randomization in February for the REMAIN-1 pivotal cohort, enrolling more than 300 participants at more than 30 sites with more than…Read full documentShow less
Interested in Fractyl Health, Inc.? Here are five stocks we like better. Revita showed durable weight-loss maintenance: Patients retained more than 80% of prior GLP-1-related weight loss one year after stopping therapy, versus 46% for sham treatment. The company also reported roughly 78% maintenance in its open-label cohort. Pivotal data and regulatory milestones are approaching: Fractyl completed enrollment in the REMAIN-1 trial, expects six-month top-line results in early Q4 2026, and is targeting a potential FDA De Novo submission later in Q4. Financially, Fractyl reported improved losses and runway: Second-quarter net loss narrowed to $25.5 million, while $47.1 million in cash is expected to fund operations into early 2027. The company does not plan to raise capital before pivotal trial results. Fractyl Health (NASDAQ:GUTS) said its Revita endoscopic procedure showed durable weight-maintenance results one year after patients discontinued GLP-1 therapy, while the company reaffirmed plans to report pivotal trial data in early fourth-quarter 2026 and pursue a potential FDA De Novo submission later in the year. Chief Executive Officer Dr. Harith Rajagopalan said the company’s strategy is centered on offering patients a one-time procedural option to help maintain weight loss after stopping GLP-1 medicines. He cited the company’s July 15 release of one-year randomized data from the midpoint cohort of the REMAIN-1 study. → MarketBeat Week in Review – 08/03 - 08/07 According to Rajagopalan, patients treated with Revita maintained more than 80% of weight loss previously achieved with GLP-1 therapy one year after discontinuation, compared with 46% in the sham group. He said the treatment effect persisted from month six through month 12 while blinding was maintained, and no participant in that cohort restarted GLP-1 therapy. Fractyl also pointed to findings from its open-label REVEAL-1 cohort, where participants maintained about 78% of prior weight loss through one year after a single Revita procedure. Rajagopalan said the results address the question of whether Revita produces sustained separation from sham treatment or merely delays weight regain. → Quantum Earnings Week: Winners and Losers Are Finally Emerging The company completed randomization in February for the REMAIN-1 pivotal cohort, enrolling more than 300 participants at more than 30 sites with more than 20 operators. Rajagopalan described the study as the largest sham-controlled gastrointestinal endoscopy pivotal trial for a novel therapeutic device. The pivotal trial was designed to enrich for two factors associated with a greater treatment effect in earlier data: complete ablation and greater run-in weight loss. The pivotal cohort had a median ablation length of 16 centimeters and a mean run-in weight loss of 18.3%, management said. → Take-Two’s Q1 Results Leave GTA 6 Bulls Stuck in the Fog of War REMAIN-1 has two co-primary endpoints. The first measures the difference between Revita and sham in percentage of total body weight regained at six months. The second is a responder endpoint requiring at least 50% of patients to maintain at least 5% total body weight loss at 12 months, based on an FDA-mandated performance goal. Rajagopalan said Fractyl estimates both endpoints are powered above 95% based on data generated to date. In the midpoint cohort, 73% of patients in the modified intent-to-treat population met the 12-month responder threshold, while the rate exceeded 90% among patients receiving complete ablations. The company said retention in the pivotal study remains above 90%, medication resumption is below its modeled assumptions, and blinded adverse-event trends remain consistent with prior studies. The final six-month study visit was scheduled for August, with database lock expected in the following weeks. Fractyl expects to report top-line six-month primary endpoint results in early Q4 2026 and top-line 12-month data in the first quarter of 2027. Rajagopalan said the final statistical analysis plan has been submitted to the FDA, and agency correspondence related to it concerned detailed elements rather than material issues. Management said it has received FDA feedback indicating that Revita’s safety profile is consistent with a moderate-risk device classification rather than a high-risk classification. The company continues to target a potential De Novo marketing submission in late Q4 after the six-month pivotal data readout, although Rajagopalan said the FDA will make its final pathway determination after reviewing the complete safety dataset. Through one year in the REMAIN-1 midpoint cohort, Fractyl reported no device- or procedure-related serious adverse events. There were four mild treatment-emergent adverse events, all of which resolved within two days, according to management. Rajagopalan said the company believes Revita could qualify for CMS transitional pass-through payment upon regulatory clearance because it holds breakthrough device designation and, in the company’s view, meets novelty and pricing-related criteria for the program. He said the applications are reviewed on a quarterly cycle and that Fractyl believes the mechanism could support reimbursement from the time of launch if the device is cleared. For commercialization, Fractyl plans a targeted center-of-excellence model focused initially on major health systems and endoscopy centers. Rajagopalan said the top 100 to 200 endoscopy health systems perform at least half of U.S. endoscopies. He said the company expects that a focused commercial team could support high-throughput centers with existing bariatric and metabolic endoscopy capabilities. The CEO said physicians generally became comfortable with the procedure in fewer than five cases in company studies, supported by a preceptorship model. He added that Revita uses skills endoscopists already possess and is intended to be a one-time, non-anatomy-altering intervention. Fractyl also reported progress for Rejuva, its gene-therapy platform. During the second quarter, the company received clinical trial authorization in the Netherlands for a Phase I/II first-in-human study of RJVA-001 and later received ethics committee approval in Australia. RJVA-001 is designed as a one-time beta cell-targeted gene therapy intended to enable nutrient-responsive GLP-1 expression in the pancreas. The candidate is delivered through an endoscopic ultrasound-guided infusion. Management said the initial trial will focus primarily on safety, tolerability, and the feasibility and safety of pancreatic delivery. The study uses staggered sentinel dosing, with the first participant monitored for at least 14 days before additional patients in that cohort can be dosed. Fractyl expects to dose the first patient after site activation and enrollment and plans to report preliminary data in the second half of 2026. Rajagopalan said the company does not yet have a timeline for seeking an FDA investigational new drug application for Rejuva. Chief Financial Officer Lara Smith Weber said second-quarter research and development expense was $13.8 million, down from $21.2 million a year earlier, primarily due to lower spending on the Revita and Rejuva programs. Selling, general and administrative expense increased to $5.3 million from $4.9 million, driven mainly by higher stock-based compensation. Fractyl reported a net loss of $25.5 million for the quarter, compared with a $27.9 million net loss in the prior-year period. Adjusted EBITDA was negative $16.3 million, improving from negative $24 million a year earlier. As of June 30, Fractyl had $47.1 million in cash and cash equivalents. Cash used in operations totaled about $16 million during the second quarter. Management said its cash runway extends into early 2027, beyond the anticipated pivotal data readout and through a potential late-Q4 De Novo submission. The company said its at-the-market facility remains closed and that it does not plan to raise capital before pivotal data are available. Fractyl Health, Inc is a clinical-stage medical technology company focused on the development and commercialization of minimally invasive, endoscopic therapies for metabolic diseases. Headquartered in Lexington, Massachusetts, Fractyl is advancing treatments that target the underlying physiology of conditions such as type 2 diabetes, obesity and nonalcoholic fatty liver disease (NAFLD) by modifying the duodenal mucosa to improve metabolic control. The company's lead product, Revita® Duodenal Mucosal Resurfacing (Revita DMR), employs a catheter-based hydrothermal ablation technique to remodel the lining of the upper small intestine. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. The article "Fractyl Health Q2 Earnings Call Highlights" was originally published by MarketBeat. View MarketBeat's top stocks for August 2026.
Related articleQuarter not tagged2026-08-10Fractyl Health Reports Second Quarter 2026 Financial Results and Business Updates
GlobeNewswire
Fractyl Health Reports Second Quarter 2026 Financial Results and Business Updates
One-year REMAIN-1 Midpoint Cohort data show Revita patients maintained up to 84% of prior GLP-1-induced weight loss versus 46% with sham in patients receiving complete duodenal ablations — the first randomized evidence of durable, drug-free weight maintenance One-year open-label REVEAL-1 Cohort data provide real-world evidence of durable weight maintenance, with patients maintaining approximately 78% of their prior GLP-1-induced weight loss after a single Revita procedure REMAIN-1 Pivotal Cohort topline data on track for early Q4 2026, paving the way for potential FDA De Novo submission in post-GLP-1 weight maintenance in late Q4 2026 Cash runway guidance into early 2027, beyond anticipated Pivotal data readout and FDA De Novo Submission Conference call today at 4:30 p.m. ET BURLINGTON, Mass., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the Company or Fractyl), a clinical stage metabolic therapeutics company focused on pioneering novel approaches to treat obesity and type 2 diabetes (T2D), today announced second quarter 2026 financial results and provided business updates. The Company also reiterated all previously disclosed 2026 Revita® clinical and regulatory milestones, including topline 6-month randomized data from the REMAIN-1 Pivotal Cohort expected in early Q4 2026, and its cash runway guidance into early 2027. “With one-year randomized data for the REMAIN-1 Midpoint Cohort and open label data for REVEAL-1 Cohort, we have the clearest evidence yet that a single Revita procedure can meaningfully reduce weight regain after GLP-1 discontinuation, with the greatest benefit observed in patients who received an adequate dose of duodenal ablation,” said Harith Rajagopalan, M.D., Ph.D., Co-Founder and Chief Executive Officer of Fractyl. “Together with a favorable one-year safety profile and cash runway into early 2027, these results give us continued confidence in the design and execution of our ongoing REMAIN-1 Pivotal Cohort, with topline six-month data on track for early Q4 2026 and a potential FDA De Novo submission to follow later in the quarter. As we approach these anticipated milestones, we are also building the commercial infrastructure needed to bring Revita to the patients with the greatest need.” Select Recent Revita Clinical Highlights Fractyl is studying Revita in the REMAIN-1 weight maintenance program, which is desig…Read full documentShow less
One-year REMAIN-1 Midpoint Cohort data show Revita patients maintained up to 84% of prior GLP-1-induced weight loss versus 46% with sham in patients receiving complete duodenal ablations — the first randomized evidence of durable, drug-free weight maintenance One-year open-label REVEAL-1 Cohort data provide real-world evidence of durable weight maintenance, with patients maintaining approximately 78% of their prior GLP-1-induced weight loss after a single Revita procedure REMAIN-1 Pivotal Cohort topline data on track for early Q4 2026, paving the way for potential FDA De Novo submission in post-GLP-1 weight maintenance in late Q4 2026 Cash runway guidance into early 2027, beyond anticipated Pivotal data readout and FDA De Novo Submission Conference call today at 4:30 p.m. ET BURLINGTON, Mass., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the Company or Fractyl), a clinical stage metabolic therapeutics company focused on pioneering novel approaches to treat obesity and type 2 diabetes (T2D), today announced second quarter 2026 financial results and provided business updates. The Company also reiterated all previously disclosed 2026 Revita® clinical and regulatory milestones, including topline 6-month randomized data from the REMAIN-1 Pivotal Cohort expected in early Q4 2026, and its cash runway guidance into early 2027. “With one-year randomized data for the REMAIN-1 Midpoint Cohort and open label data for REVEAL-1 Cohort, we have the clearest evidence yet that a single Revita procedure can meaningfully reduce weight regain after GLP-1 discontinuation, with the greatest benefit observed in patients who received an adequate dose of duodenal ablation,” said Harith Rajagopalan, M.D., Ph.D., Co-Founder and Chief Executive Officer of Fractyl. “Together with a favorable one-year safety profile and cash runway into early 2027, these results give us continued confidence in the design and execution of our ongoing REMAIN-1 Pivotal Cohort, with topline six-month data on track for early Q4 2026 and a potential FDA De Novo submission to follow later in the quarter. As we approach these anticipated milestones, we are also building the commercial infrastructure needed to bring Revita to the patients with the greatest need.” Select Recent Revita Clinical Highlights Fractyl is studying Revita in the REMAIN-1 weight maintenance program, which is designed to evaluate Revita's potential to maintain weight loss following GLP-1 based therapy discontinuation. The REMAIN-1 program includes three distinct participant cohorts that are conducted under a single IDE: the REVEAL-1 Cohort, the REMAIN-1 Midpoint Cohort and the REMAIN-1 Pivotal Cohort. In June 2026, Fractyl reported one-year data from the open-label REVEAL-1 Cohort, showing that participants who underwent a single Revita procedure experienced a mean total body weight change of 5.3% after GLP-1 discontinuation (n=15), maintaining approximately 78% of their prior GLP-1-induced weight loss. These findings provide real-world evidence and support Revita’s potential to be a compelling procedural therapy for post-GLP-1 weight maintenance. In July 2026, Fractyl reported one-year randomized data from the REMAIN-1 Midpoint Cohort demonstrating durable weight maintenance after a single Revita procedure. The treatment effect was greatest in a pre-specified optimized population, combining complete duodenal ablation (>14 cm) with higher GLP-1-induced run-in weight loss (≥17.5%), where Revita-treated participants maintained approximately 84% of their GLP-1-induced weight loss compared to 46% in sham participants (least squares mean weight regain of 4.1% versus 13.5% of body weight; n=10 versus 8 for Revita versus sham). No device- or procedure-related serious adverse events occurred through one year, and no new device-related treatment-emergent adverse events were observed between six and 12 months. These randomized, sham-controlled results provide direct read-through to the REMAIN-1 Pivotal Cohort ahead of its topline six-month readout in early Q4 2026. Commercial Readiness In June 2026, Fractyl strengthened its commercial leadership team with the appointment of Mike Zumdahl as Senior Vice President, Market Access and Commercial Strategy. Mr. Zumdahl brings experience building reimbursement and health economic infrastructure for breakthrough procedural therapies, most recently at Inari Medical, and joins Fractyl as the Company prepares for the anticipated REMAIN-1 Pivotal Cohort topline readout in early Q4 2026. Fractyl plans to provide additional detail on its commercial strategy and market opportunity at an upcoming Investor Day in September. Fractyl Forward: Reiterating Path to Pivotal Readout and Potential Regulatory Submission With one-year data now reported from both the REVEAL-1 Cohort and the REMAIN-1 Midpoint Cohort, and randomization of the REMAIN-1 Pivotal Cohort complete, Fractyl is advancing toward its two remaining anticipated 2026 milestones: pivotal readout and potential U.S. regulatory submission. The Company reiterates its previously announced cash runway into early 2027, beyond the anticipated pivotal data readout. Early Q4 2026: Topline 6-month randomized data from the REMAIN-1 Pivotal Cohort. Late Q4 2026: Potential U.S. Food and Drug Administration (FDA) De Novo marketing application submission in post-GLP-1 weight maintenance. Q1 2027: Topline one-year data from the REMAIN-1 Pivotal Cohort. As in all applications, the FDA indicated that final pathway determinations will be made following review of the complete safety dataset, which the Company intends to include in its potential De Novo marketing application submission. Rejuva® Development Progress and Anticipated 2026 Rejuva Milestones Rejuva is Fractyl’s gene therapy platform designed to enable long-term remission of T2D and obesity by durably reprogramming pancreatic islet cells to endogenously produce metabolic hormones. The lead product candidate, RJVA-001, is being advanced for patients with inadequately controlled T2D. The second candidate, RJVA-002, is a preclinical-stage dual GIP/GLP-1 gene therapy designed to treat obesity. In April 2026, Fractyl received clinical trial application (CTA) authorization for RJVA-001 in the Netherlands. Fractyl also plans to conduct the clinical trial for RJVA-001 at sites in Australia. In July 2026, Fractyl received ethics committee approval in Australia. Fractyl reiterates its anticipated 2026 Rejuva milestone: H2 2026: First-in-human dosing of RJVA-001, subject to site activation, and expected reporting of preliminary data. Second Quarter 2026 Financial Results Research and Development Expenses: R&D expenses were $13.8 million for the quarter ended June 30, 2026, compared to $21.2 million for the same period in 2025. The decrease of $7.3 million was primarily related to reduced spending on Fractyl’s Revita and Rejuva programs. Selling, General and Administrative Expenses: SG&A expenses were $5.3 million for the quarter ended June 30, 2026, compared to $4.9 million for the same period in 2025. The increase of $0.4 million was primarily driven by higher stock compensation expenses. Net Loss: For the quarter ended June 30, 2026, Fractyl reported a net loss of $25.5 million, compared to net loss of $27.9 million for the same period in 2025. The decrease in net loss of $2.4 million was driven by a $7.0 million reduction in operating expenses, $0.3 million lower non-cash loss from change in fair value of debt, $0.2 million higher interest income, partially offset by $5.1 million higher non-cash loss from change in fair value of warrant liabilities. Adjusted EBITDA: Adjusted EBITDA was negative $16.3 million for the quarter ended June 30, 2026, compared to negative $24.0 million for the same period in 2025. The decrease in the non-GAAP adjusted loss of $7.7 million was primarily due to reduced operating expenses excluding stock compensation expenses. Cash Position: As of June 30, 2026, Fractyl had approximately $47.1 million in cash and cash equivalents. Based on current business plans, the Company believes its cash position will fund operations into early 2027. Webcast and Conference Call InformationFractyl will host a conference call to discuss its second quarter financial results and provide business updates on Monday, August 10, 2026, at 4:30 p.m. ET. A live webcast of the conference call can be accessed in the “Events” section of Fractyl’s website at ir.fractyl.com. The webcast will be archived and available for replay for at least 30 days after the event. About Fractyl Health Fractyl is a clinical-stage metabolic therapeutics company advancing two differentiated candidates designed to target the root causes of obesity and T2D: Revita, a procedural therapy in pivotal development for post-GLP-1 weight maintenance, and Rejuva, an AAV-based gene therapy platform with its lead candidate RJVA-001 entering first-in-human clinical studies. Fractyl’s goal is to advance metabolic disease treatment from chronic management toward prevention and reversal of disease. Fractyl is headquartered in Burlington, Massachusetts. About Revita Revita is Fractyl’s lead product candidate, designed to remodel the duodenal lining via a one-time, minimally invasive endoscopic procedure intended to restore healthy nutrient sensing and signaling disrupted by chronic metabolic disease. Revita has received FDA Breakthrough Device designation for weight maintenance in people with obesity who discontinue GLP-1 therapies. Revita is for investigational use only in the United States and is CE marked in the European Union and United Kingdom. About Rejuva Fractyl’s Rejuva platform is developing next-generation AAV-based, locally delivered gene therapies for the treatment of obesity and T2D. Rejuva leverages advanced delivery systems and proprietary screening methods to identify and develop metabolically active gene therapy candidates targeting the pancreas, with the goal of offering novel, disease-modifying therapies that address the underlying root causes of disease. The platform’s lead candidate, RJVA-001, has received Clinical Trial Authorization in the Netherlands to initiate a Phase 1/2 first-in-human clinical trial in T2D, the first clinical-stage program from the Rejuva platform. Fractyl expects to dose the first patient with RJVA-001 and report preliminary data in the second half of 2026, subject to site activation. Fractyl also plans to conduct the clinical trial for RJVA-001 at sites in Australia and has received ethics committee approval in Australia. Additional Rejuva candidates, including RJVA-002 (a dual GIP/GLP-1 gene therapy candidate designed to treat obesity), remain in preclinical development. In the United States, Rejuva is in preclinical development. No Investigational New Drug (IND) application has been filed with the U.S. Food and Drug Administration (the FDA), and Rejuva has not been approved or authorized by the FDA for use in humans. Non-GAAP Financial Measures This press release contains certain financial information that is not presented in conformity with U.S. generally accepted accounting principles (GAAP), including Adjusted EBITDA, which is a non-GAAP financial measure as defined in Regulation G promulgated under the Securities Exchange Act of 1934. This non-GAAP financial measure is provided as supplemental information to Fractyl’s financial measures presented in this press release in accordance with GAAP. The Company defines Adjusted EBITDA as net loss adjusted to exclude (i) interest income, net, (ii) depreciation expense, (iii) stock-based compensation expense, (iv) change in fair value of notes payable and (v) change in fair value of warrant liabilities. Management believes Adjusted EBITDA provides useful supplemental information to investors regarding the Company’s core operating performance and facilitates period-to-period comparisons by excluding items that are non-cash or non-operational in nature and may vary in magnitude. Adjusted EBITDA is also used by management in evaluating the Company’s operating performance and in planning and forecasting activities. The non-GAAP financial measures used by Fractyl may not be the same or calculated in the same manner as those used and calculated by other companies. Non-GAAP financial measures have limitations as analytical tools and should not be considered in isolation or as a substitute for Fractyl’s financial results prepared and reported in accordance with GAAP. This non-GAAP measure should not be construed as an inference that the Company’s future results will be unaffected by unusual or non-recurring items. A reconciliation of Adjusted EBITDA reported in this press release to the most comparable GAAP measure for the respective periods appears in the table captioned “Reconciliation of GAAP Net Loss to Adjusted EBITDA” later in this press release. Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact are forward-looking statements. These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will” and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, without limitation, statements regarding: the expected initiation, timing, design, endpoints, site activation, and conduct of the RJVA-001 first-in-human clinical trial in the Netherlands and the RJVA-001 clinical trial in Australia; the timing and results of first-in-human dosing and reporting of preliminary data; Fractyl’s regulatory strategy, including submissions to and communications with regulators in the European Union, Australia, and other jurisdictions; the promise, potential impact, and mechanism of action of RJVA-001 and Fractyl’s Rejuva platform; Fractyl’s anticipated financial performance, including cash and cash equivalents, for any period of time; Fractyl’s expected cash runway; the promise and potential impact of Fractyl’s preclinical or clinical trial data and product candidates, including Revita’s potential for maintaining weight loss after GLP-1 based therapy discontinuation; the design, initiation, timing and results of clinical enrollment and any clinical studies or readouts, including readouts from the REVEAL-1 Cohort, the REMAIN-1 Midpoint Cohort and the REMAIN-1 Pivotal Cohort; the content, information used for, timing or results of any Investigational New Drug (IND)-enabling studies, IND applications, or CTAs; communications with regulators regarding the REVEAL-1 Cohort, the potential launch or commercialization of any of Fractyl’s product candidates or products, the REMAIN-1 Midpoint Cohort and the REMAIN-1 Pivotal Cohort; the potential treatment population or benefits for any of Fractyl’s product candidates or products; Fractyl’s regulatory strategy, including potential use and benefits of the De Novo pathway (FDA pre-submission feedback is advisory and non-binding, and there is no assurance that FDA will accept a De Novo marketing application submission or that the Revita DMR System will receive marketing authorization); Fractyl’s commercial readiness activities and the development of commercial infrastructure; the timing and content of any planned Investor Day or similar event; Fractyl’s strategic and product development objectives and goals; and the timing of any of the foregoing. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause Fractyl’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the risks that are discussed more fully in Fractyl’s filings with the Securities and Exchange Commission (the SEC) including the “Risk Factors” section of Fractyl’s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 24, 2026, and other documents Fractyl subsequently files with or furnishes to the SEC, including Fractyl’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, filed with the SEC on August 10, 2026. These forward-looking statements are based on management’s current estimates and expectations. While Fractyl may elect to update such forward-looking statements at some point in the future, Fractyl disclaims any obligation to do so, even if subsequent events cause Fractyl’s views to change. Contact Brian Luque, Head of Investor Relations and Corporate [email protected], 951.206.1200 (1) Working capital is defined as total current assets less total current liabilities.
TranscriptFY2026 Q22026-08-10FY2026 Q2 earnings call transcript
Earnings source - 72 paragraphs
FY2026 Q2 earnings call transcript
Good afternoon, and welcome to Fractyl Health's second quarter 2026 financial results and business update call. As a reminder, this conference call is being recorded. At this time, all participants are on listen-only mode. There will be a Q&A session following management's prepared remarks. I will now turn the call over to Brian Luque, Head of Investor Relations and Corporate Development at Fractyl. Brian, you may now begin.
Thank you. This afternoon, we issued a press release that outlines the topics we plan to discuss today. This release is available at www.fractyl.com under the Investors tab. Joining us on the call today are Dr. Harith Rajagopalan, Chief Executive Officer, and Lara Smith Weber, Chief Financial Officer. During this call, we make forward-looking statements which involve risks and uncertainties that may cause actual results to differ materially from our forward-looking statements. We provide a comprehensive list of risk factors in our SEC filings, including the quarterly report on Form 10-Q filed today, which I encourage you to review. Any forward-looking statements on the call are subject to substantial risks and uncertainties, speak only as of the call's original date, and we undertake no obligation to update or revise any of the statements, even if subsequent events cause the company's views to change.
It is now my pleasure to pass the call over to Harith.
Thank you, Brian. Good afternoon, everyone. Nearly 30 million Americans are now on GLP-1 therapy. Approximately one million are discontinuing each month. What happens after discontinuation is now well-characterized. On average, patients regain roughly 60% of their prior weight loss within 12 months of stopping therapy, and cardiometabolic benefits begin to erode even earlier. For many patients, the choice is either to resume chronic pharmacotherapy or accept substantial weight regain. We believe Revita has the potential to offer a third option, durable drug-free weight maintenance following a one-time endoscopic procedure. A year ago, that was our thesis. Now, we have the first randomized sham-controlled evidence supporting that thesis one year after GLP-1 discontinuation and the most direct read-through to the REMAIN-1 pivotal cohort expected in early Q4. On our last three calls, I laid out four pillars that give us conviction in Revita. First, the clinical signal is real.
Second, our pivotal study is built to win. Third, there is a clear path to commercial value. Fourth, we are funded through definitive data later this year. Let me take each of them in turn, but I will spend most of my time on the commercial opportunity today. Pillar one, the clinical signal is real. On July 15, we reported one-year randomized data from the REMAIN-1 midpoint cohort. The study asked a simple question. One year after stopping a GLP-1 therapy, how much of the weight loss do patients keep? Revita patients maintain more than 80% of their prior GLP-1 induced weight loss at one year, compared with 46% in the sham arm. The treatment effect held from month six through month 12 under maintained blinding in a cohort where not one patient reinitiated GLP-1 therapy.
An additional piece of confirmatory evidence. The open-label REVEAL-1 cohort showed a consistent signal in June, with participants maintaining approximately 78% of their prior weight loss through one year after a single procedure. So we now have two different patient populations showing one year of durable weight maintenance and compelling effect size after Revita. This directly addresses the most important question about our six-month data presented earlier in the year. Were we producing durable separation or simply delaying weight regain? Dr. Adarsh Thaker of UCLA, a principal investigator on REMAIN-1, named that concern on our July call and told us that the curves are now showing hints of a plateau at the one-year mark. Two details sit behind those numbers. The strongest results came in patients who achieved complete ablations and higher run-in weight loss, the two variables the pivotal study is enriched for.
The sham arm behaved as published literature would expect and predict, providing strong external validity to the study outcomes. I would like to spend a minute on safety and tolerability because I believe it is one of the largest single drivers of Revita's eventual adoption. Through one full year, there were zero device- or procedure-related serious adverse events. In fact, in the midpoint cohort, there were only four mild treatment-emergent adverse events in the entire study, all resolved within two days. For a procedural therapy in obesity, this is an unusually clean profile, and it is the reason we believe adoption by physicians and patients may be substantial. Compare this profile with the only alternative these patients have today. GLP-1 medicines are associated with high rates of GI adverse events. The more potent the agent, the more adverse events.
Primary care providers are already referring patients to gastroenterologists to help manage these GI side effects. That potential to address a real concern for patients is why a gastroenterologist is prepared to offer this procedure to the patient who walks into clinic or the endoscopy suite, and why a patient who cannot or will not stay on a GLP-1 is willing to try it. Pillar two, the pivotal, is built to win. The REMAIN-1 pivotal cohort is a larger, well-powered version of the midpoint cohort, just run larger. Same patient profile, same protocol, same investigators, same blinded dietician oversight. It is the largest sham-controlled GI endoscopy pivotal trial for a novel therapeutic device ever conducted. We completed randomization in February with more than 300 participants across more than 30 sites with more than 20 operators.
Importantly, the pivotal is enriched for the two variables that were associated with greater treatment effect. The threshold for a complete ablation is 14 centimeters. In the pivotal, the median ablation length is 16 centimeters, and the mean is closer to 17. The threshold for higher run-in weight loss is approximately 17.5%. In the pivotal, the mean run-in weight loss is 18.3%. We have two co-primary endpoints, and based on the data we've generated to date, we estimate both are well powered above 95%. The first is percent total body weight regain between Revita and sham at six months. The required margin is a separation of roughly 2.5 percentage points, and the midpoint MITT result using the pre-specified statistical analysis plan submitted to the FDA clears that comfortably. The second is the responder rate.
The FDA-mandated pre-specified performance goal is a single-arm result of at least 50% of patients maintaining at least 5% total body weight loss at 12 months. In the midpoint cohort, that figure was 73% in the MITT population and above 90% in the complete ablation population. Every operational metric that we believe is important to the pivotal success continues to track favorably. Retention remains well above 90%. Medication resumption remains below our modeled assumptions. The blinded adverse event profile remains consistent with what we have seen across prior studies, reinforced by our DSMB interactions. We remain on track to report top-line six-month primary endpoint data in early Q4 2026 and expect to report top-line 12-month data from the REMAIN-1 pivotal cohort in Q1 2027.
On the regulatory front, we have favorable FDA feedback in hand that Revita's safety profile is consistent with a moderate risk rather than a high-risk device classification. We remain on track for a potential De Novo submission in late Q4 2026 following the six-month pivotal data readout. As with all applications, final pathway determination will follow FDA's review of the complete safety data set, which we intend to include in the submission. Pillar three: the path to commercial value. One overarching point, the trends that are shaping the GLP-1 market strengthen Revita's commercial opportunity. They expand the addressable market, they increase the potential treatment effect, or they improve the economics, and often all three at once. We will take you through the detail at our Investor Day in September. First, the market opportunity is well understood by all key stakeholders.
FDA has granted Revita breakthrough device designation for post GLP-1 weight maintenance. CMS has begun covering GLP-1s for weight loss while openly raising concerns about frailty and about the affordability of a therapy taken for life. Physicians are already fielding the question. Patients are asking obesity medicine specialists how long they need to stay on the medicine at the moment they are provided the first prescription, and gastroenterologists are now taking referrals for GLP-1 side effects with no off-ramp to offer as of yet. Here is the part I think is most underappreciated. It does not need a new site of care either. These patients are already in GI clinics and GI labs every day, and the endoscopy suites, physician expertise, and clinical workflows are already in place. Second, we view the oral era as a demand engine.
One question we often hear is whether more convenient GLP-1 therapies reduce the need for Revita. The evidence to date suggests the opposite. Most oral GLP-1 initiations are new prescriptions rather than switches, and there is no evidence that oral formulations lower the barrier to stopping. Every initiation, oral or injectable, is a potential future discontinuation and need for an off-ramp. Third, the next generation of these medicines may increase rather than diminish Revita's treatment effect. As next-generation therapies deliver even more weight loss, the need for a durable off-ramp only grows. In the REMAIN program, the placebo-adjusted Revita treatment effect in the midpoint cohort increased with greater run-in weight loss. The more weight a patient lost on drug, the greater the weight regain after discontinuation, and the larger the measured Revita benefit. Fourth, payers are converging on the need for a durable solution.
A major development this year was the introduction of the Medicare GLP-1 Bridge demonstration, having gone live on July 1st in a population that has both the highest obesity prevalence and high discontinuation risk. CMS administrators expect single-digit million number of patients under Medicare to be on GLP-1s within the next year. The Bridge program sunsets at the end of 2027, and the major payer objection is not that obesity treatment does not work. Their concern is the affordability of treatment that continues indefinitely, together with poor adherence and high discontinuation in real-world practice. That is exactly the challenge Revita is designed to address. Pillar four: we are funded through definitive data. Fourth and finally is our capital situation. Lara will take you through the quarter in detail, but let me state our posture plainly. We ended the quarter with $47.1 million in cash.
Our runway extends into early 2027, beyond the pivotal data readout and through a potential De Novo submission. Our ATM facility remains closed. We do not plan to raise capital before we have pivotal data in hand. The marked reduction in cash outlay in the second quarter versus the first or versus last year reflects the completion of pivotal randomization and sustained fiscal discipline across the organization. This is a deliberate choice grounded in conviction. We believe the pivotal data will be positive, and we are choosing to operate inside our existing capital envelope through the most consequential two quarters in this company's history as a signal of management alignment with shareholders. Turning briefly to Rejuva, our smart GLP-1 gene therapy platform targeting long-term metabolic remission from a single dose. In Q2, we received clinical trial authorization in the Netherlands to initiate the phase I/II first-in-human study of RJVA-001.
We have also now received ethics committee approval in Australia. We believe RJVA-001 is the first AAV-based gene therapy candidate to enter clinical development for type 2 diabetes. 001 is a one-time beta cell-targeted gene therapy designed to enable nutrient-responsive physiologic GLP-1 expression within the pancreas, delivered by a minimally invasive endoscopic ultrasound-guided infusion. The design intent is to avoid the high circulating drug levels that drive the side effects associated with systemic GLP-1 therapy. The primary objective of the first-in-human study is to evaluate the safety and tolerability of 001, together with the feasibility and safety of delivery to the pancreas using the Rejuva system. Secondary objectives include assessment of glycemic effect using continuous glucose monitoring and mixed meal tolerance testing, characterization of GLP-1 secretion, and evaluation of immune response.
The study uses staggered sentinel dosing, in which the first participant is monitored for a minimum of 14 days and their safety data reviewed before any additional participants in that cohort are dosed. We expect to dose the first patient subject to imminent site activation and patient enrollment, and to report preliminary data in the second half of this year. Importantly, Rejuva's clinical development is funded within our existing runway and does not compete with Revita for capital. Before I hand to Lara, here is our near-term calendar. In early September, we will host an Investor Day to walk through the commercial opportunity, our market access strategy, and the health economics work our new Senior Vice President of Market Access and Commercial Strategy, Mike Zumdahl, and his team have been leading. In early Q4, we anticipate reporting top-line six-month randomized data from the REMAIN-1 pivotal cohort.
In late Q4, we anticipate our potential FDA De Novo marketing application submission, and in Q1 next year, we anticipate reporting top-line 12-month data from the REMAIN-1 pivotal cohort. Lara?
Thank you, Harith. Research and development expenses were $13.8 million for the second quarter of 2026, compared with $21.2 million for the same period in 2025. The decrease of $7.3 million was primarily related to reduced spending on our Revita and Rejuva programs. SG&A expenses were $5.3 million for the quarter, compared with $4.9 million for the same period in 2025. The increase of $0.4 million was primarily driven by higher stock compensation expense. We reported a net loss of $25.5 million for the second quarter of 2026, compared with a net loss of $27.9 million for the same period in 2025. The $2.4 million decrease was driven by a $7 million reduction in operating expenses, partially offset by a $5.1 million higher non-cash loss from the change in fair value of our warrant liabilities, with smaller movements in debt fair value and interest income
Adjusted EBITDA was negative $16.3 million for the quarter, compared with negative $24 million in the second quarter of 2025, a $7.7 million improvement driven by reduced operating expenses excluding stock compensation. As of June 30th, 2026, we had $47.1 million in cash and cash equivalents. I want to draw your attention to one point on run rate. Our first quarter carried certain one-time costs associated with completing REMAIN-1 pivotal cohort randomization. The second quarter does not. Cash used in operations was approximately $16 million in Q2, which is a better reflection of our post-randomization run rate than Q1. Based on our current business plans, we believe our cash position will fund operations into early 2027, beyond the anticipated REMAIN-1 pivotal data readout in early Q4 2026, and through a potential De Novo submission in late Q4. With that, I'll turn it back to Harith.
Thank you, Lara. Let me close where I started with our four pillars. First, the clinical signal is real. We now have randomized, sham-controlled one-year data showing 80% GLP-1-induced weight loss maintained versus 46% with sham. Second, the pivotal is built to win in that it's the same experiment run larger, powered above 95% on both co-primary endpoints, and enriched on both of the variables we now know drive effect size. The last six-month visit happens this month, and we remain on track to report top-line data in early Q4. Third, the path to commercial value is clear, and we are building on it now rather than waiting. The market already exists. The patients are already seeing GI physicians, and payers are converging on the need for a durable alternative. Fourth, we are funded through definitive data. Our runway extends into early 2027.
There is no planned raise before pivotal data. I want to thank the patients in our pivotal study who have trusted us with their health and their persistence, and the investigators and operators who have executed this trial with real skill. I want to thank our employees, whose focus through an unusually demanding stretch has been exceptional. I want to thank our shareholders, whose conviction in this science makes all of it possible. Operator, we are ready to take questions.
Thank you. At this time, we'll conduct a question-and-answer session. As a reminder to ask a question, you will need to press star one one on your telephone and wait for your name to be announced. To withdraw your question, please press star one one again. Please stand by while we compile the Q&A roster. Our first question comes from the line of Michael Dufour of Evercore ISI. Your line is now open.
Hey, guys. Thanks so much for taking my questions. Two for me. One regarding profitability. I think in the past you said that you believe that Fractyl can be profitable with a targeted launch into the top 100 to 200 U.S. centers. My question is, what procedure volume per center is embedded in that profitability assumption, and how quickly do you expect trained physicians to ramp to that level? Then I have a follow-up.
Well, that's actually a wonderful question that preps for our Investor Day that's coming in early September, where we can address our view on the commercial opportunity ahead of us. I'm not going to front-run with specific numbers in that regard. I will say that embedded in that is also the health economic value from Revita, and we are finalizing our numbers now. With 50 patients, with one year of follow-up from REVEAL and REMAIN, we believe that the health economic value proposition is greater than we had previously realized. That helps us gain confidence in the potential profitability from the health economic value we can deliver. With respect to your question on training, as we've observed now across multiple studies, it takes less than five procedures for a physician to feel comfortable doing our procedure.
We expect to continue the same preceptorship program that we ran in our pivotal study, quite successfully, I might add, as we get new physicians comfortable with using this procedure. The benefit that we have is that the procedure that we're asking them to learn how to do leverages existing skills, doesn't really ask them to do anything that they don't otherwise know how to do, and therefore can be very easy for them to intuitively understand what needs to happen. From a patient perspective, the advantage is that this is a one-time intervention that is not anatomy altering and has what we believe to be a very compelling safety profile. That's why we think it's going to be compelling to both physicians and patients.
But more numbers on the model should be presented as a story in our Investor Day with an understanding of the health economic value as well.
Great. Thanks, Harith. I have one more follow-up question regarding reimbursement. Just trying to get a sense if there's any, I guess, remaining risk on the patient coverage side. Like what criteria do you expect payers or Medicare to impose around prior GLP-1 use, the degree of prior weight loss, BMI, documented discontinuation, et cetera, before reimbursing for Revita? Thank you.
I expect that payers will be looking very carefully at the patient population that was studied and pre-specified in the pivotal trial. While I can't speak to what the label might say, I would expect that the payers are going to look very carefully at this at least 15% run-in weight loss and the use of a GLP-1 therapy or GLP-1-based therapy rather than tirzepatide specifically. This is an interesting conversation that we will look forward to having with pivotal data in hand with payers. I can tell you that in the conversation we've had in the last quarter with payers, Medicare in particular is concerned about the muscle mass loss associated with the GLP-1s and the frailty as it particularly applies to the elderly population.
Combined with the fact that they're expecting millions of people to start GLP-1s because of this bridge program and because that program has a shelf life of about 18 months, there is clearly a view that a lot of patients will be needing to be discontinuing next year, and they're thinking hard about what the implications of that are.
Very helpful. Thank you.
Thank you.
Thank you. One moment for our next question. Our next question comes on the line of Jason Gerberry of Bank of America. Your line is now open.
Hey, guys. Thanks for taking my questions. Another one on reimbursement. Upon approval, what is the expectation in terms of how the transitional coverage for emerging technologies, given that you have breakthrough device designation, are there any risks to that? In terms of when you would be filing, anything you need to be aware of in terms of the importance of filing timeline and/or De Novo versus a PMA filing? That is my first question. Secondly, you mentioned in the press release, the company building out commercial infrastructure for Revita as the data readouts approach. Can you maybe just elaborate a little bit more on those efforts? What sort of size of commercial infrastructure that you believe you will need to support Revita? Thanks.
Sure. With respect to initial payment, there is a mechanism called transitional pass-through through CMS that has a quarterly review cycle and a statutory requirement for payment that is actually quite clear. Breakthrough devices have an exemption through transitional pass-through, meaning that breakthrough devices that achieve regulatory clearance or approval are automatically in scope so long as they are novel and so long as the price of that novel device does not fit into an existing CPT schema. Ours, we believe, fits all of those criteria. The applications go in on a quarterly basis. They are reviewed in a rolling manner, and every three months, new approved or cleared devices get transitional pass-through payment.
We feel like the tailwinds are strong in that the CMS just issued a new rule reaffirming that transitional pass-through rule, that criteria that I just laid out will be in place for the next several years, and we believe we will qualify once cleared. That allows us to have confidence that Revita can have reimbursement from day one at the time of launch, which is a really strong place to be. That ties to our view on the commercial infrastructure. We will have more to say about this in our September Investor Day, but the high-level points that I would want to convey are that we envision a very targeted and efficient center of excellence model focused on hospitals where we already have very strong relationships.
As Mike alluded to earlier, the top 100 to 200 endoscopy health systems do at least half of the endoscopies in the U.S. All of these top centers have endoscopists who are focused on doing bariatric and metabolic endoscopy. We have strong relationships there, and we will initially focus on them because we believe that health systems can funnel patients in very efficiently, enabling us to launch with a smaller team that is highly focused on high-throughput centers.
Thank you. One moment for our next question. Our next question comes from the line of Chase Knickerbocker of Craig-Hallum. Your line is now open.
Good afternoon. Thanks for taking the questions. Maybe just first from me, could you just confirm whether or not the final SAP was submitted and if there was any response or correspondence with the agency as it relates to some of the recent tweaks? Thanks.
Yes, final SAP was submitted. I think we mentioned that in our July call, and we are locked and loaded heading into our database lock in the next several weeks.
Was there any response or kind of correspondence with FDA as it was kind of around that?
There was. There was clearly a response from the FDA. It's all sort of within the nuances. I would say that it was down in the schema of details rather than high level. Nothing of materiality for us to discuss.
Great. Just last, a little bit of a kind of bigger picture question. Can you just remind us the extent of your patent estate as it relates to other kind of ablation technologies, particularly as it relates to weight maintenance as we think about now having a De Novo approval rather than a PMA? Can you just speak to your patent protection?
Sure. Well, one thing that I would say at a very high level is that we have a very broad and comprehensive patent estate that ties to our company being the leader in innovation in this category and being the first to develop any form of ablation efforts for the duodenum, whether that's in type 2 diabetes or in weight maintenance or in NAFLD, NASH or other metabolic conditions that you could imagine. We have issued patents in the U.S. that cover not only our methods and our specific devices, but also broadly covering both thermal and non-thermal ablation modalities, not only for post GLP-1 weight maintenance, but also for type 2 diabetes and related conditions. So we believe that we have a very strong patent estate covering any manner of ablation modality, and we intend to defend that market.
Great. Thanks, Harith.
Thank you.
Thank you. One moment for our next question. Our next question comes from the line of Whitney Ijem of Canaccord Genuity. Your line is now open.
Hey, guys. Thanks for taking our question. This is Angela on for Whitney. You talked earlier in the call about more patients being on GLP-1 injectable or orals now, and that each patient is a future discontinuation, so the addressable market has really also expanded. Curious, though, from your market research, are you seeing patients perhaps maybe stay on drug longer, or is that discontinuation rate still about the same at one year? Just thinking about physicians now having more experience with this class of medications and being able to titrate.
The data that I'm seeing is that patients are all the meta-analyses I'm seeing are now suggesting that the median duration of time on therapy is still in the six to nine month range. I have not seen anything change, but I would also say the quality of our data is more impaired because of more people getting drugs from online pharmacies. The best data that we have suggests that people are on drug for about six to nine months. I'm very intrigued to see, but it's too early to tell, what that median duration of therapy will be on orals. Preliminarily, what we're seeing with orals is that people are staying on lower doses or not titrating nearly as much as one might have expected.
We are going to be continuing to follow that very carefully and then thinking about how that models into our estimation of the total market size. But the million discontinuers a month, I think, is still the most jaw-dropping number and important to think about because these patients, if they've been on drug for six to nine months months, have probably gotten to clinically meaningful weight loss and now are facing rapid weight regain. Based on what we've seen in our own clinical trials, it's happening in the sham arm in these patients. I expect that's happening consistent with what's happening in the real world. We think we have a really huge opportunity here.
Thank you. One moment for our next question. Our next question comes from the line of Mike Ulz of Morgan Stanley. Your line is now open.
Hi, this is Rohan for Mike. Thanks for taking our questions. On Revita, can you just talk about any early thoughts on pricing? On Rejuva, what kind of preliminary data should we expect later this year? Thanks.
Okay. So on Revita pricing, the health economic analysis that we're doing, we're going to be presenting in our Investor Day later this month. It's a bit premature for me to give you that number, but we can present our view on the health economic value proposition. We will be planning to do so in just a few weeks. With respect to Rejuva, I would point you to our earlier statement that the first most important thing for us to communicate is the safety and tolerability of RJVA-001 through that first 14-day sentinel period and the safety and feasibility of the Revita device delivery. That's the most important thing because that's what unlocks the rest of the dosing in the dosing cohort. So I would point you to that as the first thing that we're going to be communicating.
Thank you.
Thank you. One moment for our next question. Our next question comes from the line of Jeffrey Cohen of Ladenburg Thalmann. Your line is now open.
Hello, Harith and Lara. Thanks for taking our questions. Two, firstly, although it's a secondary endpoint, could you comment at all on HbA1c and what you would anticipate the readout of Revita in early Q4 would show? Would you expect that to be comparable with previous cohorts?
So we do have secondary analyses in the REMAIN pivotal study for effects on cardiometabolic parameters, lipids like HDL and triglycerides, and HbA1c. This is a patient population that does have a fair amount of obesity-related comorbidity, but very few of these patients actually were diagnosed with pre-diabetes at the time of randomization. The signal that we would hope to be able to show is glycemic stability through six months in that blinded randomized trial. I don't think the HbA1cs at the time of randomization were very high. They were in the low fives.
I don't think you're going to expect to see something more than glycemic stability, which I think alone is a very valuable thing because these patients are at high risk of going on to developing pre-diabetes, and that will take more time to mature in a clinical signal than the six-month readout is going to give you.
Okay, that's helpful. As a follow-up, could you jump over to Rejuva for a moment? I think the Netherlands study is three cohorts, three patients, with an additional 20 behind that. What's expected for Australia?
Well, it's all one study, actually. It's not just Netherlands. There are multiple sites in an international study. Each cohort across the study will have three patients across the study, whether it's in Netherlands or Australia or elsewhere.
So we would anticipate seeing nine patients by the end of the year?
No, no. We have to dose the first patient, wait 14 days, see a safety signal before we can dose anybody else. I think the thing to focus on, as I mentioned, is initial safety and feasibility of the device delivery, and then safety and tolerability in that first sentinel patient through 14 days. That is the thing that is going to give us the necessary information that would then allow the dosing of additional patients based on the protocol.
Got it. Thanks for the clarification. Thanks for taking our questions.
Thank you.
Thank you. One moment for our next question. Our next question comes from the line of Joe Pantginis of H.C. Wainwright. Your line is now open.
Hey guys, good afternoon. Thanks for taking the question. My questions are both regulatory-based. First, with Revita, curious, what would you describe as the key outstanding point or points with regard to going down the De Novo status, number one, and then what would you describe as the key points to be able to get to IND status in your discussions with the FDA? Thanks a lot.
Okay. The key point to get Revita De Novo is their review of our safety data from our pivotal study. That's very clear. That's going to go in with the submission, and given the fact we have only seen blinded safety data with DSMB regular reviews, we are very encouraged by the safety profile in the blinded analysis. The FDA will need to review that and then make a final determination. We feel good about where we stand. With respect to Rejuva, our plan will be to generate safety, feasibility, and preliminary efficacy data from this OUS first-in-human study before coming to talk to the FDA. We don't yet have a timeline for you on when that will be.
Got it. Appreciate the details, Harith.
Yeah. Thank you.
Thank you. I'll now turn the call back to Dr. Rajagopalan for closing remarks.
Well, thank you, everyone. Investor Day next month. Appreciate the commercial questions. Look forward to discussing them in much more detail with you in early September. Top-line pivotal data in early Q4, potential De Novo submission late Q4. We are one quarter away from the most important question in obesity. Thank you all.
This concludes today's conference call. Thank you for participating. You may now disconnect.
Related articleQuarter not tagged2026-08-03Fractyl Health to Report Second Quarter 2026 Financial Results and Provide Business Updates on August 10, 2026
GlobeNewswire
Fractyl Health to Report Second Quarter 2026 Financial Results and Provide Business Updates on August 10, 2026
BURLINGTON, Mass., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the Company or Fractyl), a clinical-stage metabolic therapeutics company focused on pioneering novel approaches to treat obesity and type 2 diabetes (T2D), today announced that it will report financial results for the second quarter 2026 and provide business updates on Monday, August 10, 2026, at 4:30 p.m. ET. A live webcast of the conference call and presentation can be accessed in the “Events” section of Fractyl Health’s website at http://ir.fractyl.com. The webcast will be archived and available for replay following the live event. About Fractyl Health Fractyl Health is a clinical-stage metabolic therapeutics company advancing two differentiated candidates designed to target the root causes of obesity and T2D: Revita, a procedural therapy in pivotal development for post-GLP-1 weight maintenance, and Rejuva, an AAV-based gene therapy platform with its lead candidate RJVA-001 entering first-in-human clinical studies. Fractyl’s goal is to advance metabolic disease treatment from chronic management toward prevention and reversal of disease. Fractyl is headquartered in Burlington, Massachusetts. Contact Brian Luque, Head of Investor Relations and Corporate [email protected], 951.206.1200

